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ABSTRACT 
Background: Heparin and protamine dosing for anticoagulation during cardiopulmonary 
bypass (CPB) and its reversal after CPB, respectively, is usually given according to body 
weight. Excess protamine may impair coagulation. The HeProCalc algorithm calculates 
heparin and protamine doses during the procedure. Platelets play a crucial role in coagulation 
and haemostasis after cardiac surgery and platelet malfunction may explain excessive bleeding 
after CPB. Patients on clopidogrel and aspirin undergoing coronary surgery with CPB risk 
excessive bleeding. Between 2008-2012, the European Medicines Agency (EMA) suspended 
the marketing authorization of aprotinin, but Swedish hospitals received permission to continue 
its use.  
Aims: To investigate whether the HeProCalc algorithm affects heparin and protamine dosing, 
postoperative blood loss, and transfusion rate (Study I+II), whether ROTEM®platelet provides 
additional information to ROTEM® analysis in guiding platelet transfusions after cardiac 
surgery and identifying factors triggering platelet administration (Study III), and to compare 
aprotinin use in coronary surgery during 2006‒2007 vs. 2008‒2014, before and after the EMA 
suspension (Study IV). 
Methods: In Study I and II 40 and 210 patients, respectively, undergoing cardiac surgery with 
CPB were randomized to heparin and protamine dosage based on body weight only or the 
HeProCalc algorithm. In Study III ROTEM® and ROTEM®platelet were analysed before 
anaesthesia (T0, n=23), after CPB (T1, n=23) and after platelet transfusion (T2, n=10). In Study 
IV consecutive patients on clopidogrel and aspirin undergoing coronary surgery with CPB and 
received aprotinin 2006-2014 were included.  
Results: Study I: Equal doses of heparin were given in both groups, but there were lower mean 
doses of protamine in the HeProCalc vs. the control group (211±56 vs. 330±61mg, p<0.001). 
Postoperative bleeding was less in the HeProCalc group (280±229 vs. 649±279mL, p=0.074). 
Study II: Total protamine dose was 210mg (interquartile range [IQR] 190-240) in the 
HeProCalc group vs. 350mg (IQR 300-380, p<0.001) in the control group. The ratio of total 
protamine to initial dose of heparin in the HeProCalc group was 0.62 vs. 1.0 (p<0.001). 
Bleeding after 12 hours was 320mL (IQR 250-460) in the HeProCalc group vs. 350mL (IQR 
250-450, p=0.754) in the control group. Transfusion rate did not differ sign. between groups. 
Study III: ROTEM® and ROTEM®platelet tests were all significantly reduced between T0 and 
T1. ROTEM® parameters improved sign. after platelet transfusion. Only ROTEM®platelet 
TRAPTEM increased between T1 and T2 (p=0.008). Factors triggering platelet transfusion 
were long duration of surgery and time on CPB. Study IV: After 2007, aprotinin was restricted 
to patients on clopidogrel with platelet aggregation <85% on day of surgery. Use of aprotinin 
decreased from 113 patients/year 2006‒2007 to 6 patients/year 2008‒2014. Mean EuroSCORE 
I and mean CPB time were sign. higher in the second period, indicating greater operative and 
bleeding risk. No sign. differences were observed regarding mortality, complications, bleeding 
and transfusion rates between the two periods. 
Conclusions: Study I: HeProCalc-based dosage of heparin and protamine allowed for reduced 
protamine use after CPB compared with conventional calculations. Furthermore, HeProCalc-
based regimen for heparin reversal suggested less postoperative bleeding, although the 
difference between the groups was not statistically significant. Study II: Use of the HeProCalc 
algorithm reduced protamine dosage and the protamine/heparin ratio after cardiopulmonary 
bypass compared with conventional dosage based on weight without significant effect on 
postoperative blood loss or the transfusion rate. Study III: ROTEM®platelet TRAPTEM 
improvement indicated that platelet transfusion may reverse CPB induced platelet dysfunction. 
Study IV: Aprotinin use decreased sign. after 2007. Despite a higher operative risk and longer 
CPB duration, patients given aprotinin between 2008 and 2014 did not differ sign. in outcomes 
and transfusion rates compared with those treated with aprotinin during the prior 2 years. 
  
 Populärvetenskaplig sammanfattning 
Genom att använda en hjärtlungmaskin övertar den hjärtats och lungornas uppgifter att pumpa 
runt blodet i kroppen respektive att syresätta blodet. Dock medför den kontinuerliga passagen 
av patientens blod genom hjärtlungmaskinen och att blodet kommer i kontakt med luft en 
kraftig aktivering av koagulations (blodets förmåga att levra sig) - och immunsystemet. För att 
förhindra att blodet koagulerar sig tillför man det blodförtunnande läkemedlet heparin innan 
patienten ansluts till hjärtlungmaskinen. Heparinet har en snabb effekt och man kan efter att 
hjärtlungmaskinen infrånkopplats neutralisera heparinets blodförtunnande effekt med 
läkemedlet protamin. Höga doser protamin försämrar dock till viss del blodets förmåga att 
koagulera, vilket kan öka blödningen och behovet av blodtransfusioner efter en hjärtoperation. 
För att undvika detta kan man individanpassa doseringen av protamin på olika sätt, t.ex. genom 
att använda dataprogrammet HeProCalc. Effekten av detta program studerades i Delarbetena 
I och II. 
I Delarbete III studerades effekten av hjärtkirurgi med hjälp av hjärtlungmaskin på 
blodplättarnas funktion. Vid blödningsproblematik efter en hjärtoperation kan blodplättar 
tillföras via transfusion och blodpättarnas koagulationsförmåga mättes före och efter 
hjärtlungmaskinanvändningen samt efter transfusion av blodplättar. 
Patienter med instabil kranskärlssjukdom tillförs blodplättshämmande läkemedlet t.ex. 
clopidogrel för att förhindra att en hjärtinfarkt uppstår innan patienten antingen genomgår en 
kranskärlsoperation eller en ballongvidgning. I de fall då en hjärtinfarkt är hotande och 
patienten måste genomgå en akut kranskärlsoperation kan man inte vänta tills clopidogrelets 
effekt försvunnit. Detta innebär en risk för livshotande blödning och stort transfusionsbehov i 
samband med operationen. Riskerna kan dock minskas genom att tillföra läkemedlet aprotinin 
i samband med operationen. En kanadensisk studie indikerade dock 2008 en association mellan 
aprotinin och ökad mortalitet vid hjärtkirurgi, varför aprotinin blev indraget i de flesta 
västerländska länder förutom Storbritannien och Sverige. Efter rigorös myndighetsgranskning 
ansågs studien vara opålitlig och aprotinin blev åter fritt att använda 2016. I Delarbete IV 
studerades effekten av aprotinin hos patienter som genomgick akut kranskärlsoperation under 
behandling med clopidogrel före och efter 2008.  
Sammanfattningsvis visade Delarbetena I och II att användningen av dataprogrammet 
HeProCalc minskade protamindosen med ca 30% jämfört med traditionell dosering baserat på 
vikt. I Delarbete III påvisades en signifikant sänkt blodplättsfunktion mätt med tre olika 
delmetoder efter frånkopplad hjärtlungmaskin. Efter transfusion av blodplättar var det endast 
en av dessa tre delmetoder som uppvisade en signifikant förbättring. I Delarbete IV visade sig 
de patienter, som opererats 2008-2014 trots högre operativ risk och längre tid i 
hjärtlungmaskin, inte ha signifikant skilda kliniska resultat eller transfusionsbehov jämfört med 
de patienter som opererats 2006-2007. 
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1 INTRODUCTION AND BACKGROUND 
1.1.1 Excessive bleeding in cardiac surgery    
Excessive perioperative bleeding in cardiac surgery is associated with risk for serious 
complications including infections,1, 2 respiratory and renal failure,3 neurological events,3 and 
mortality.3-6 The etiology of excessive bleeding in cardiac surgery is multifactorial. Medication 
with anticoagulants and platelet inhibitors, activation of inflammatory systems via blood 
contact with the surfaces of the cardiopulmonary bypass (CPB) circuit, the negative effects on 
blood coagulation by shear stress generated by pumps and cardiotomy suction devices, 
hypothermia, and hemodilution are some important factors that may influence hemostasis 
during and after CPB.7 Moreover, adequate estimation of platelet function, appropriate 
measures to counteract dual antiplatelet therapy (DAPT), and  optimization of heparinization 
during CPB and the following reversal of heparin with protamine after CPB are other 
challenges to attain postoperative hemostatic control. 
1.1.2 Heart-lung machine and cardiopulmonary bypass 
The first successful heart operation with support from a heart-lung machine was performed 
in the United States 1953 by John Gibbon when he managed to close an atrial septal defect 
in an 18-year-old woman. One year later, the Swedish surgeon Clarence Crafoord, together 
with the surgeon Viking Olof Björk, Åke Senning and engineers from AGA AB, Stockholm, 
Sweden, developed their own heart-lung machine, which was used when they performed a 
successful removal of a cardiac myxoma at Sabbatsberg’s Hospital in Stockholm. There was 
an urgent need for effective anticoagulation during the clinical use of heart-lung machines, 
and at that time approval from ethical boards or medical agencies were not needed. Thus, 
Clarence Crafoord and his team just administered heparin to these patients to prevent 
perioperative thrombembolic complications. By doing that, Clarence Crafoord together with 
Erik Jorpes, contributed considerably to the clinical use of heparin during CPB, which still 
today is the gold standard for anticoagulation during CPB. During the next decade the use of 
heart-lung machines in cardiac surgery escalated all over the world thanks to adequate 
anticoagulation with heparin and enabled advanced cardiac surgery during cardiac arrest.  
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1.1.3 The heart-lung machine 
The heart-lung machine used for CPB consists of several parts (Figure 1).  Venous blood is 
drained from the heart usually via a cannula in the right atrium or in each of the caval veins 
and collected into an external venous blood reservoir, before the venous blood is pumped 
through an oxygenator by a roller or centrifugal pump. By passing the oxygenator the venous 
blood becomes oxygenated and carbon dioxide is removed. The gas flow rate and oxygen 
percentage of the sweep gas ventilating the oxygenator determine oxygen saturation and 
carbon dioxide pressure in outgoing arterial blood. The oxygenator is also connected to a 
heater/cooler system with which temperature of the passing blood is controlled. After 
oxygenation, the now arterialized blood returns to the patient via an arterial cannula, normally 
placed in the ascending aorta. Blood circulating in the CPB circuit with its tubing gets in 
contact with the main pump and with additional pumps and tubes that are used for suction of 
blood from the surgical field to the venous reservoir and for delivery of cardioplegia solution. 
Altogether blood passing the CPB circuit gets in contact with 2-3 m2 of foreign surfaces.  
 
FIGURE 1. An illustration of the different components of the cardiopulmonary bypass system, which when in 
contact with blood contribute to the activation of inflammation- and the coagulation system. Blue color depicts 
venous desaturated blood, red arterial oxygen saturated blood, green blood from the aortic root/left ventricle 
from the bottom of the open surgical field, and yellow blood which is transported via the coronary suction 
device from the surgical wound to the venous reservoir.  
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The used pump flow rate is related to the patient´s body surface area, temperature and 
hematocrit, and normally a pump flow rate of 2.4 L/m2/minute is used during normothermia. 
During surgery, there is sometimes need for hypothermia as a measure to decrease oxygen 
requirement. In situations requesting circulatory arrest, body temperature is often decreased 
to 28-24°C, although sometimes to <18°C, when selective cerebral perfusion is omitted, as 
the latter temperature is the threshold when the brain becomes isoelectric. Other reasons 
requiring a lower pump flow and hypothermia can be an unsatisfactory venous return or 
special surgical technical reasons, such as minimizing blood in the surgical field.  
  
1.1.4 Inflammatory activation 
CPB and surgical trauma will induce pronounced effects on the hemostasis, including systemic 
inflammatory response, leukocyte activation and the release of inflammatory mediators. 
Platelets activated by surgical trauma including contact with the inner surface of the CPB 
circuit will interact with activated leukocytes and amplify the inflammatory reaction to CPB. 
Factor XII will attach to high-molecular-weight kininogen (HMWK) and the complex then 
sticks to the non-physiologic surface. This complex releases FXIIa, kallikrein and bradykinin 
and the intrinsic coagulation cascade starts (Figure 2).  
The coagulation and inflammatory systems interact closely trigger each other. Coagulation is 
activated as a response to inflammation, and simultaneously, thrombin and FXa act as 
proinflammatory agents. Altogether, the processes are caused both by blood contact with 
foreign surfaces lacking factors that normally inhibits complement activation and the surgical 
trauma but also by hypoperfusion, ischemia and tissue reperfusion8  induced by CPB and aortic 
cross-clamping and de-clamping, respectively.  
After end of CPB, protamine is given to neutralize heparin, forming a heparin-protamine 
complex, which will specially trigger cytokines, a process not observed during off-pump 
surgery9, 10. Furthermore, hypothermia, release of thrombin, tissue plasmin activator  and FXII 
will stimulate the fibrinolytic process. The effects on the inflammatory system and hemostasis 
are enhanced by prolonged CPB as well as deep hypothermia.10  
Clinical symptoms of extensive systemic inflammatory activation include loss of vascular tone 
and leakage of capillary fluid, resulting in need for volume substitution during CPB, which in 
turn will aggravate hemodilution. Vasodilation will induce the need for vasoconstrictive 
medication effecting the microcirculation in the tissues. These reactions may in some patients 
lead to post-CPB effects including low cardiac output, respiratory or renal failure. 
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FIGURE 2. An illustration of some key coagulation and in inflammatory factors activated during cardio-
pulmonary bypass (CPB). 
 
1.1.5 Coagulation activation  
The delicate balance of clot formation and bleeding is critically disturbed during cardiac 
surgery and CPB. The disruption is caused by blood being exposed to non-physiologic surfaces, 
sub-atmospheric pressure and shear stress. We attempt to set the coagulation system “on hold” 
during CPB using full heparinization. Still hemodilution caused by CPB prime effects not only 
platelets but all coagulation factors as well. Moreover, CPB prompts consumption of 
coagulation factors, e.g. fibrinogen levels decrease by 36% and platelet count by 45%,11 which 
together all contribute to the fact that cardiac surgery involving CPB is associated with 
increased blood loss and a high frequency of transfusion of allogeneic blood products.  
 
CPB
FXII FXIIa
Kallikrein Prekallikrein
Plasminogen Plasmin
Fibrin	degradation	
productsFibrin
CONTACT	ACTIVATION	
ISCHEMIA	
REPERFUSION
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FIGURE 3. An illustration of the two pathways including activation of coagulation factors that in the end lead to 
fibrin clot. TF, Tissue Factor; HMWK, High Molecular Weight Kininogen. 
As shown in Figure 3 above, activation of FXII is caused both by activation of the 
inflammation system and the blood contact with the CPB circuit, whereas tissue damage leads 
to activation of tissue factor and FVII. Both pathways in the end lead to fibrin clots. Boisclair 
et al. showed that the main trigger of coagulation during cardiac surgery and CPB was the 
tissue factor-factor VIIa activation in response to the cutting of tissue.12 
  
Use of hypothermia during CPB is associated with increased postoperative bleeding, 
decreased platelet aggregation and thrombin release. Both acidosis and hypothermia promote 
coagulopathy, the three factors included in the “lethal triad of trauma”. Moreover, 
hypothermia will decrease synthesis of clotting factors and delay initiation of thrombi and 
clots.13 
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1.1.6 Platelet activation 
Many of the reactions in the coagulation process take place on the surface of platelets, which 
makes them essential in this context. Despite their tiny size, 2-3 µm in diameter, platelets 
represent a considerably amount of total cell mass in the body due to their concentration of 
150-300 x 109/L in blood. Their life span ranges between 5-10 days and young platelets are 
most reactive.14  
Exposure to air, negative pressure and shear stress activate platelets and initiate conformational 
change, depletion of granule content and expression of various receptors that enhance 
aggregation and further activation. This pronounced reaction results in a decrease both in 
platelet count and function11, 15, illustrated by a decrease in 70%, 65% and 54% in the 
Adenosine diphosphate (ADP) test, cyclooxygenase (COL) test, and Thrombin receptor-
activating peptide-6 (TRAP) test, respectively, with Multiplate®.11 Hemodilution affects 
platelets, concentration of coagulation factors and hemoglobin, resulting in less margination of 
platelets towards the vessel wall that further aggravates the impaired coagulation.16 Other 
reasons of decreased platelet count include mechanical disruption and adhesion to the non-
physiologic surface along with sequestration in organs. Importantly, reduction in platelet count 
together with dysfunction is the principal cause of bleeding and coagulopathy after cardiac 
surgery.17 Furthermore, thrombin release caused by surgical trauma will activate platelets with 
ensuing effect on coagulation. Moreover, platelet count in circulating blood decreases 
markedly during CPB 7, 18 and a low postoperative platelet count has been linked to increased 
postoperative blood loss.19, 20 Remaining platelets after cardiac surgery show a diminished 
response capacity to stimulation and although they recover within a few days, this is 
challenging as their contribution to coagulation early after surgery is critical. 
Additional to platelet dysfunction related to CPB and cardiac surgery is the fact that some of 
these patients are on DAPT with one ADP-receptor blocker, e.g. clopidogrel, ticagrelor, or 
prasugrel, and aspirin. Preferably, the ADP-receptor blockers are discontinued well in time 
before surgery and according to current European association for cardio-thoracic surgery 
(EACTS)/ European association for cardio-thoracic anesthesiology (EACTA) guidelines21 
surgery should preferably be postponed at least 3, 5 and 7 days after intake of ticagrelor, 
clopidogrel, and prasugrel, respectively. However, in emergency surgery this is not possible. 
Consequently, patients who need urgent coronary surgery while on DAPT are at risk for 
increased bleeding.22 Several observational studies have shown that clopidogrel exposure 
within 5‒7 days prior to coronary surgery to be linked to an augmented risk of major bleeding, 
reoperation, and transfusions.23 On the other hand, withholding DAPT prior to urgent surgery 
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puts the patient at risk of thrombotic events.22 Point-of-care test (POC)-testing of platelet 
function may be of use to identify coronary patients at risk of excessive blood loss.24-27  
The different platelet inhibitors used for DAPT may have different effects on platelet 
transfusion. In contrast to clopidogrel and prasugrel that bind irreversibly to circulating 
platelets, platelet bound ticagrelor may also inhibit transfused platelets, making platelet 
transfusion less effective.28 
Platelet transfusion per se might imply a risk of adverse events such as allergic reactions, 
infections and stroke according to a meta-analysis of six randomized, double blinded, placebo 
controlled trials involving aprotinin versus placebo, whereby the effects of platelet transfusion 
was compared in those transfused (n=284) with those not transfused (n=1436).29 30 Van Hout 
et al.31 reported that cardiac surgery patients receiving platelet transfusion in the operating room 
(OR) suffered less postoperative blood loss, but more often needed vasoactive drugs, prolonged 
ventilation, prolonged intensive care and blood products postoperatively. However, in that 
small recent publication, where 169 patients were retrospectively propensity matched with 507 
controls,31 platelet transfusion was not associated with reoperation for bleeding, 
thromboembolic events, infections, organ failure, or mortality. There is according to Levy et 
al.32, who reviewed 8 studies, no consensus regarding guidelines for transfusion of platelets. 
This impedes the ability to draw conclusions and highlights the requirement for further studies 
to evaluate the proper dose and triggers for platelet transfusion in perioperative patients.32  
The EACTS/EACTA guidelines21 only state, based on the clinical and practice guideline from 
the American Association of Blood Banks33, that platelets may be transfused in patient bleeding 
postoperatively if the platelet count is less than 50 x 109 /L or if the patient is on antiplatelet 
drugs.  
 
1.2 DRUGS WITH IMPACT ON COAGULATION AND INFLAMMATION 
1.2.1 Heparin 
To prevent microscopic clot formation or, in worst case, a life-threatening massive thrombus 
formation in the CPB circuit, adequate anticoagulation is required. Since the discovery by 
McLean in 1916, heparin remains the most commonly used drug for anticoagulation during 
CPB even 100 years later. Swedish biochemist J. Erik Jorpes at Karolinska Institutet is credited 
with identifying the chemical structure of heparin in 1935, which made it possible for the 
Swedish company Vitrum AB to launch the first heparin product for intravenous use in 1936.  
  8 
The polysaccharide heparin, which is the strongest macromolecular acid in the body, has a 
molecular weight ranging from 3000 to 40 000 Dalton with a mean mass of approximately 
15 000 Dalton. The varying molecular weight between heparin batches also may explain why 
their potency often differ. In cardiac surgery, heparin is administrated via a central venous 
line and the maximum activated clotting time (ACT) prolongation is achieved within five 
minutes. As heparin is a large molecule with a strong negative charge, extravasal distribution 
is unlikely to take place. Heparin exerts its effect by potentiating anti-thrombin (ATIII) a 
thousand times, thus also depressing effects of activated factors, IX, X, XI, XII, XIII and 
thrombin.7 Even though heparin exerts its effect by potentiating ATIII 1,000-fold, the 
variation in response cannot be explained only by the ATIII level.34 Levels of ATIII may be 
low preoperatively due to a daily treatment with low-molecular heparin or may decrease 
during surgery as a result of hemodilution and consumption during CPB. The binding of 
heparin to ATIII requires a heparin molecule with length of 18 saccharides, while a heparin 
molecule with only five saccharides is enough to inhibit factor Xa (Figure 4). Heparin also 
stimulates the release of tissue factor pathway inhibitor (TFPI) from endothelia cells.35   
 
FIGURE 4. Catalysis of ATIII-mediated inactivation of thrombin by heparin (Weitz 1997, with permission from 
New England Journal of Medicine). 
 
Heparin is primarily eliminated by the reticuloendothelial system (RES), a component of the 
immune system, in a rapid dose-dependent way. When endothelial cell binding of heparin 
gets saturated, some heparin is cleared by the renal system but with a slower elimination 
rate.35 Hypothermia is known to delay elimination of heparin due to induced decrease in 
enzyme activity. On the contrary, CPB-rewarming will increase heparin consumption and 
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lower ACT values and thus increase the risk thromboembolic events if not adequate doses of 
additional heparin are given. High heparin doses are used in connection with the CPB, and 
the elimination rate is slower when high doses are used. The mean half-life for a bolus dose 
of 400 International Units (IU)/kg is 152 minutes, while the mean half-life for 100 IU/kg is 
approximately 60 minutes,36 To complicate matters further, there is substantial variability of 
heparin anticoagulant responsiveness among patients undergoing cardiac surgery, thus 
making dosing sometimes difficult. 
1.2.2 Protamine 
After end of CPB, normalization of coagulation is facilitated by neutralization of heparin with 
protamine, a polycationic protein derived from salmon sperm. Heparin, with its strong negative 
charge, binds ionically to the positively charged protamine. Protamine both neutralizes heparin 
and exerts a mild anticoagulant effect, which is independent of heparin.7 The half-life of 
protamine is approximately five minutes and protamine is nearly completely eliminated from 
the circulation within 20 minutes.37 
In contrast to the non-toxic heparin, protamine may induce severe adverse anaphylactic 
reactions due to release of histamine from mast cells including severe hypotension, high 
pulmonary arterial pressure, and bronchospasm.38 Administration of excess doses may also 
have a negative effect on coagulation, including platelet dysfunction, down regulation of 
thrombin generation by inhibition of factor V, and weakened clot structure.39, 40 Kunz et al.41 
concluded in a retrospective study that a higher protamine/heparin weight ratio was associated 
with a larger hemoglobin drop, higher chest tube output and increased risk of blood transfusion. 
Commonly, a fixed dose of 1.0 to 1.3 mg of protamine is used to neutralize each mg (100 IU) 
of given heparin, although it can be based either on initial or total given dose of heparin.21 
Moreover, although 84% of international centers add heparin to the prime of the CPB circuit,42 
it is in most studies unclear if this dose really is added to the total given dose of heparin. The 
reversal dose with protamine does not account for heparin elimination during CPB and might 
result in an excess protamine dosage after CPB.43 Protamine titration and a low dose protamine 
regime after termination of CPB have been suggested by The Society of Cardiovascular 
Anesthesiologists (SCA), the Society of Thoracic Surgeons (STS) and the American Society 
of ExtraCorporeal Technology (AmSECT)44 and the European Association of CardioThoracic 
Surgery/European Association of CardioThoracic Anaethesiology  (EACTS/EACTA) in their 
guidelines regarding blood conservation clinical practice.44 The EACTS/EACTA guidelines 
specifically state that “protamine should be administered in a protamine-to-heparin dosing 
ratio <1:1 to reduce bleeding”.45 
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1.2.3 Aprotinin 
Extracted from bovine lung tissue, aprotinin is a naturally occurring serine protease inhibitor 
that forms reversible complexes with many enzymes and factors including kallikrein (promotes 
contact activation, Figure 5), trypsin, chymotrypsin, plasmin, elastase, thrombin, active protein 
C (cleaves and degrades factor V), and tissue plasmin activator. The most important proteases 
inhibited by aprotinin are plasmin and kallikrein, whereof plasmin is the final enzyme in the 
fibrinolytic pathway.  
The latest Cochrane review of anti-fibrinolytic use for minimizing packed red blood cells 
(PRBC) transfusion and reoperation due to bleeding is from 2011.46 It evaluated 252 
randomized controlled trials (RCT) of anti-fibrinolytic drugs in adults scheduled for non-urgent 
surgery that recruited over 25,000 participants, whereof 69% of the patients underwent cardiac 
surgery. Compared with control aprotinin (RR 0.66; 95% CI 0.60 to 0.72), tranexamic acid 
(TXA, RR 0.61; 95% CI 0.53 to 0.70) as well as epsilon aminocaproic acid (EACA, RR 0.81; 
95% CI 0.67 to 0.99) reduced number of PRBC transfusions. However, aprotinin alone when 
compared with TXA/EACA significantly reduced transfusion rate of PRBC (RR 0.82; 95%CI 
0.71- 0.95) as well as re-operation rate due to bleeding (RR 0.67, 95% CI 0.46-0.98). 
Aprotinin is considered to attenuate the inflammatory cascade, which also modulates 
fibrinolysis and coagulation. Furthermore, reducing inflammatory response will preserve 
platelet function and thereby decrease its effect on the coagulation system. Thus, aprotinin 
deems to have anti-inflammatory properties, at least when the high dose regimen, also known 
as the full Hammersmith regimen, is used. The enzymatic activity of aprotinin is expressed in 
Kallikrein Inhibiting Units (KIU), with 1 KIU equivalent to the amount of aprotinin that 
decreases the activity of 2 biological kallikrein units by 50%. The high dose regimen consists 
of an intravenous bolus of 2 x 106 KIU as a loading dose, followed by 0.5 x 106 KIU/h during 
surgery, and 2 x 106 KIU in the CPB circuit prime. Lower-dosing regimens are not considered 
to provide a full anti-inflammatory effect.  
By inhibiting thrombin activation of protease-activated receptor-1 on platelet activation during 
CPB, aprotinin reduces the activation and depletion of platelets during CPB, which allows 
platelets to retain their function perioperatively. By interacting with kallikrein at higher doses, 
aprotinin inhibits the intrinsic pathway of coagulation, possibly decreasing over-consumption 
of coagulation products during CPB.  
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FIGURE 5. An illustration of some key coagulation and in inflammatory factors activated during cardio-
pulmonary bypass (CPB) and the influence of aprotinin. 
Contradicting many earlier randomized studies, including three meta-analyses,47 two large 
propensity matched observational studies by Mangano et al. 48, 49 indicated that, when 
compared with lysine analogs or a control group, perioperative treatment with aprotinin 
significantly increased the risk of renal, cardiac or cerebral events, as well as mortality. 
However, the findings may be explained by inappropriate heparin dosing during CPB in a few 
participating centers that did not take in to account that aprotinin markedly prolongs celite 
based ACT results. The findings contradicted earlier observational studies by other 
investigators 50-52 except that the use of aprotinin in coronary artery bypass grafting (CABG) 
may be associated with slight transient creatinine increase.53 In 2008, a large randomized trial, 
the Blood conservation using antifibrinolytics in randomized trial (BART) study,54 was 
published, which evaluated aprotinin versus lysine analogs in patients categorized as “high risk 
cardiac surgery patients”. In this study, a tendency to an increased mortality in those patients 
receiving aprotinin was observed in an interim analysis by an independent data and safety 
monitoring committee, whereby the study was terminated earlier than planned. After 
publication of the BART study, where aprotinin was found to significantly increase 30-day 
mortality after surgery compared with TXA/EACA, aprotinin was withdrawn from the world 
market and for a period only available for licensed use. However, in the BART study 52% of 
eligible patients were excluded from randomization indicating a possible selection bias. 
Furthermore, after a comprehensive review by Health Canada and European Medicines 
Agency (EMA),55 some serious limitations of the BART study were identified. There was an 
CPB
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unexplained exclusion of 137 patients from analysis after randomization and the excluded 
group included several dead patients, none of whom received aprotinin. Moreover, there was 
an unusually large number of reclassifications of outcomes from the originally reported data, 
with a large (∼75%) change rate in primary outcome (massive postoperative bleeding). The 
reclassifications were in opposite directions for aprotinin versus TXA and EACA, favoring the 
latter, and these changes increased with the duration of the study. As a result, an editorial 
entitled “Aprotinin and cardiac surgery: a sorry tale of evidence misused” was published in 
the in the British Journal of Anaesthesia.56 
A re-analysis including originally excluded patients showed no statistical significance of the 
mortality signal for aprotinin. Because of the serious doubts regarding the correctness of the 
analysis, Health Canada and the EMA have rejected the BART study. As a consequence, 
aprotinin has gradually been reregistered and is currently available for use in cardiac surgery.57 
However, although EMA now approves the use of aprotinin in cardiac surgery, EMA requires 
on-line registration of patients receiving aprotinin to monitor its on- and off-label use.  
Aprotinin augments ADP-induced platelet aggregation in patients on clopidogrel.58 
Furthermore, two randomized controlled trials showed that aprotinin reduced postoperative 
bleeding and transfusion rate in patients on DAPT requiring urgent or acute CABG.59, 60 To 
our knowledge, no studies have presented the clinical use of aprotinin during the above 
mentioned, rather long suspension period, during which alterations in medical practice are 
likely to have occurred. Consequently, the EMA encouraged publishing of data about clinical 
use of aprotinin during this period, 2008-2014. An additional argument is the change of 
aprotinin manufacturer from Bayer AG (Leverkusen, Germany) to Nordic Group B.V. 
(Hoofddorp, the Netherlands), whereby Sweden received aprotinin from Nordic group since 
2008. Furthermore, any European center using aprotinin since its relicensing must report 
clinical patient outcome to the Nordic Aprotinin Patient Registry (NAPaR), which is 
sponsored by Nordic Group, and NAPaR subsequently reports to the EMA.  
Between 2008 and 2012, the use of aprotinin was approved by the national health authorities 
with a license from the Swedish Medical Agency. At Karolinska University Hospital, use of 
aprotinin continued during this period resulting in a database including several hundred patients 
who before and after 2008 underwent CABG and were given aprotinin. 
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1.3 COAGULATION MONITORING 
1.3.1 Activated Clotting Time  
ACT measures the anticoagulant effect of heparin. This test was introduced by Hattersley 
and Blakely in the 1960´s and is the gold standard for analyzing the heparin anti-coagulation 
effect when high doses are used, e.g. during CPB. This point of care test measures time to 
clot formation in seconds and is based on coagulation activation of whole blood with either 
kaolin or celite. Low ACT levels indicate an increased risk of thrombus formation in the CPB 
circuit. Many studies have been made to define the optimal ACT level for CPB. Even though 
there is no universal agreement, a minimum of 400 seconds is often referred to as a standard 
level regarding safety concerns7 and current clinical practice guidelines recommend an ACT 
>480 seconds.44 Besides heparin, other factors affecting ACT include hemodilution, 
hypothermia, low platelet count, coagulation deficiencies, and medications such as warfarin, 
platelet inhibitors, and thrombin inhibitors.61  
 
To ensure that no remaining heparin is present after protamine reversal, a High Range 
Heparinase Cartridges (HTC, Medtronic, Minneapolis, MN, USA) analysis along with a 
standard ACT test, both analyzed with the Medtronic ACT Plus® System (Medtronic, 
Minneapolis, MN, USA) may be performed. One channel of the test includes heparinase and 
will present an ACT value reflecting unheparinized blood, whereas the standard ACT channel 
will identify the eventual presence of heparin.  
1.3.2 Rotational Thromboelastometry (ROTEM)®   
The rotational thromboelastometry, ROTEM® (TEM International, Munich, Germany), is a 
whole blood viscoelastic test measuring coagulation in real-time. The indication for using this 
test is mainly excessive or uncontrolled bleeding. This point-of-care test includes analysis of 
the external coagulation pathway, EXTEM®, the internal coagulation pathway, INTEM®, 
fibrinogen concentration, FIBTEM® and heparin presence, HEPTEM®, and gives the first 
results within 10 minutes. The use of ROTEM testing has been shown to decrease cost and 
transfusion requirements when used in cardiac surgery.62 
1.3.3 ROTEM®platelet  
It would be valuable if platelet function after cardiac surgery could be appropriately evaluated, 
to understand when and when not, platelet transfusions are indicated. Assessment of 
coagulation with ROTEM® has been reported to provide valuable information in deciding 
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therapy to optimize coagulation in patients bleeding after cardiac surgery.63 Yet, the ROTEM® 
method is of limited value for assessment of platelet function. 
Testing with ROTEM®platelet (TEM International, Munich, Germany) is quick POC test for 
possible 24/7 use. It is based on impedance aggregometry of whole blood, similar to Multiple 
Electrode Aggregometry (MEA; Multiplate Verum Diagnostica, Roche, Munich, Germany),15 
and has primarily been used for detection of platelet inhibition by anti-platelet drugs. The gold 
standard method for platelet function, Light Transmission Aggregometry (LTA), is not a POC-
test and thus of limited value in acute situations. Both ROTEM® and ROTEM®platelet can be 
analyzed with the same instrument. Three different agonists are used; with ARATEM, 
activation is achieved with arachidonic acid (AA), with ADPTEM activation is achieved with 
ADP and with TRAPTEM platelets are activated with TRAP. Testing with ROTEM®platelet 
has shown that cardiac surgery with CPB impairs platelet function in all assays. 64  
1.3.4 Plateletworksâ    
Several platelet function tests are available for evaluation of platelet function. The 
Plateletworksâ (Helena laboratories, Beaumont, TX, USA) assay is dependent on single 
platelet counting with a conventional cell counter before and after agonist stimulation in vitro. 
Test results are available within minutes, but a requirement is that the testing needs to be 
performed within 10 minutes after blood sampling. 
1.3.5 HeProCalc guided perfusion system 
The computer algorithm HeProCalc (HeProCalc AB, Huddinge, Sweden) is designed to 
optimize dosage of heparin and protamine with respect to patient’s body surface area and the 
baseline ACT value. During CPB, all ACT values are measured and continuously inserted in 
the computer program along with data regarding additional heparin doses and temperature of 
the arterial line of the CPB system, to calculate the need for additional heparin during CPB and 
ideal protamine dose after termination of CPB. During CPB, the computer algorithm presents 
the calculated ACT value, the heparin consumption/minute and the calculated total heparin 
amount existing in the circulation expressed as IU/kg. 
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2 AIMS 
The specific aims were to: 
• Analyze HeProCalc-based dosage of protamine compared with traditional calculation 
of protamine dosage based on body weight. 
 
• Investigate whether postoperative blood loss and transfusion requirement differed 
between HeProCalc-based dosage of protamine and traditional calculations of 
protamine dosage based on body weight.  
 
• Investigate whether analysis with ROTEMâplatelet may provide additional 
information to conventional ROTEMâ analysis regarding platelet function after CPB 
and after platelet transfusions. 
 
• Compare demographic and procedural characteristics as well as clinical outcomes of 
patients who underwent CABG surgery and received aprotinin during two time periods, 
2006‒2007 and 2008‒2014, before and during aprotinin´s European suspensio
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3 METHODS 
3.1 STUDY DESIGN AND PATIENT SELECTION 
 
Study I and Study II (NCT02785575) were prospective, double-blinded (only Study II), 
randomized, single-center trials. Patient inclusion was performed between October and 
November 2013 (Study I) and during the period April through September 2016 (Study II). All 
included patients were scheduled for elective, and urgent cardiac surgery on CPB due to 
cardiovascular and/or valve diseases. Patients undergoing surgery involving planned 
hypothermia <34°C (Study I) or <32.0°C (Study II) were also excluded, as a severe 
hypothermia might affect coagulation and thus interpretation of results. Patients unable to give 
informed consent and those with known coagulation defects were not included (Study I-III). 
Warfarin therapy was discontinued at least three days before surgery, but aspirin was continued 
until day of surgery (Study I-IV). ADP-receptor inhibitors and new oral anticoagulant drugs 
were discontinued five respectively three days before surgery (Study I-III). None of the 
patients received fondaparinux less than 24 hours prior to surgery (Study I-III). 
In Study III we prospectively included patients over 18 years of age, electively scheduled for 
extensive cardiac surgery with CPB for example combined valve replacement, redo´s, or 
complex aortic arch surgery between January and October 2016. The selected patients were 
planned to undergo complex surgery with a presumed high risk of bleeding and thereby 
transfusion of platelets.  
Study IV was an observational, retrospective, single tertiary center study where we reviewed 
the medical records of 268 consecutive patients, who underwent isolated first-time on-pump 
CABG and received aprotinin between 2006 and 2014. During this period, aprotinin was given 
to patients undergoing cardiac procedures if they were at high risk for excessive bleeding or 
had been receiving clopidogrel within 5 days before surgery. 
Study I-IV were performed at the Department of Cardiothoracic Surgery and 
Anesthesiology, Karolinska University Hospital, Stockholm, Sweden.  
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3.2 CLINICAL PRACTICE 
3.2.1 Cardio pulmonary bypass system 
In Study I-III, Sorin’s open CPB system (Sorin Group, Milan, Italy) was applied for CPB, and 
includes a single chamber hard shell venous reservoir, the Revolution centrifugal pump, and a 
phosphorylcholine coated oxygenator with an integrated arterial filter. Priming consisted of 
1,100 to 1,500 mL of Ringer’s acetate (Baxter, Deerfield, IL USA); 250 mL of mannitol 15% 
(Baxter); and 5,000 (Study I) or 7,500 IU (Study II-III) of heparin (heparin and protamine, 
Leo Pharmaceutical, Copenhagen, Denmark). The dose of heparin added to the CPB-prime 
was not included in the calculation of total given dose of heparin. All patients in Study I-III 
received tranexamic acid (Pfizer Inc, New York, NY) with a bolus of 10-20 mg/kg before the 
start of the operation, followed by an infusion of 5-10 mg/kg/h during the operation, depending 
on the patient’s renal function. 
3.2.2 Activated clotting time measurements 
Study I-II: For ACT measurements, we used kaolin reagent-based Medtronic high-range ACT 
cartridges with the Medtronic ACT Plus System and the Medtronic high-range heparinase test 
cartridges were used to detect any remaining heparin after administration of calculated 
protamine dose. In this test, the cartridge consists of two channels of which one contains 
purified bacterial heparinase that rapidly destroys any heparin left in the blood by enzymatic 
cleavage of linkages at the ATIII binding site. The amount of heparinase present in the channel 
will neutralize 6 units of heparin /ml of blood. The other channel in the cartridge is a standard 
high-range ACT. The heparinase channel will show a clotting time reflecting the ACT value 
of unheparinized blood while the standard ACT channel will identify the eventual presence of 
heparin in whole blood. If a difference between the two channels is detected this would imply 
that the sample could contain heparin. A value out of range in the heparinase channel indicates 
that other factors than heparin, such as low levels of fibrinogen, platelet dysfunction, or dilution 
of the sample, is causing the high ACT-value. Prior to induction of anesthesia, a radial artery 
blood sample was taken for baseline ACT. Samples for identifying any remaining heparin 
effect were drawn at three minutes after administration of protamine and one hour after surgery. 
The ACT limit for starting CPB was 480 seconds. We analyzed ACT every 30 minutes during 
CPB or more frequent if the ACT value was volatile. 
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3.2.3 Assessment of platelet inhibition 
In Study IV, we assessed Adenosine DiphosPhate (ADP)-induced platelet aggregation with 
the Plateletworks® assay. The test must be performed <10 minutes after blood sampling. 
Baseline platelet count was measured after addition of 1 ml whole blood to the 1st 
Plateletworks® tube, which was primed with synthetic anticoagulant 
ethylenediaminetetraacetic acid (EDTA). Thereafter, one milliliter of whole blood was added 
to the 2nd Plateletworks® tube, which contained citrate and 20 µmol of ADP inducing platelet 
aggregation (Figure 6). Platelet count was thereafter measured for each tube with a cell counter 
(ABX Micros 60; Horiba ABX Diagnostics, Holliston, Massachusetts). As platelet aggregates 
exceed normal platelet size, the cell counter discriminates between aggregated and non-
aggregated platelets based on size. The difference in platelet count between the two samples 
was used as an assessment of platelet aggregation, resulting in a percentage platelet inhibition 
from 0 to 100%.  
 
FIGURE 6. Agonist-induced platelet aggregation with examples of platelet count (reprinted with 
courtesy of Helena Laboratories) 
3.2.4 Change in clinical use of aprotinin 
 
Study IV: Before 2008, aprotinin was used in patients undergoing cardiac surgery if they 
were at high risk for excessive bleeding or had been taking clopidogrel within 5 days before 
surgery. In 2008, the clinical management was changed at our hospital: 1) platelet function 
testing (Plateletworks®) was used to assess platelet aggregation in all patients receiving 
clopidogrel within 5 days before surgery; 2) as a consequence of the BART study54 and the 
suspension of aprotinin’s market authorization, aprotinin was restricted to patients on 
clopidogrel and with platelet aggregation <85% on day of surgery; and 3) when possible, 
surgery was delayed until platelet aggregation was >85% after suspension of clopidogrel. 
Thus, these factors restricted the administration of aprotinin in our department after 2007. 
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3.2.5 HeProCalc guided perfusion system 
The HeProCalc computer program has been developed to optimize heparin and protamine 
dosing in cardiac surgery. By using an empirically developed algorithm based on patients´ age, 
sex, height, weight, and baseline ACT, the HeProCalc calculates the initial dose of heparin. 
The program tracks and continually calculates the heparin concentration, consumption rate, as 
well as timing and requirement for supplemental heparin to the individual patient during CPB, 
by repeated input of measured ACT values, temperature, and additional doses of heparin and 
time points for these events.  Furthermore, the algorithm calculates and continually updates the 
heparin concentration, and suggests additional ATIII when the calculated heparin concentration 
surpasses 600 IU/kg. After weaning from CPB, the algorithm estimates the protamine dose 
based on all the patient´s ACT values, and the quantity of heparin given over time. The target 
ACT was set to 550 seconds to give a border of safety if the onset of CPB would be postponed.  
3.2.6 ROTEM® and ROTEM®platelet 
 
FIGURE 7. Principle functional outline of the ROTEM®, which is a whole blood viscoelastic test 
measuring coagulation in real time. 
ROTEM®, a viscoelastographic whole blood test, is used to evaluate coagulation status. The 
clot formation is presented as four graphs, representing plasma coagulation, fibrinogen and 
platelet function, and fibrinolysis. To perform the test, a citrated whole blood sample is added 
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to a heated cup, in which calcium and tissue factor are inserted to induce clot formation (Figure 
7). A rotating pin is submersed into the cup and as clotting initiates resistance increases. The 
changes in mechanical resistance are measured, calculated and transformed into graphs and 
numbers. In Study III, three tests were carried out; INTEM, EXTEM and FIBTEM and 
variables examined were clotting time (CT: time to initiation of clot formation, measured in 
seconds) clot formation time (CFT: time to reach a certain clot strength, measured in seconds), 
and maximum clot firmness (MCF measured in mm). CT reflects plasma coagulation, while 
CFT and MCF mirror fibrinogen levels and platelet function (Figure 8). FIBTEM is used to 
distinguish between the platelet and fibrinogen contribution to clotting. 
 
FIGURE 8. A depiction of the ROTEM®, a viscoelastographic whole blood test, demonstrating coagulation status 
in real time as clot initiation, propagation, stabilization, and lysis. See text for description of parameters. 
 
3.2.7 ROTEM®platelet assay 
The ROTEM®platelet assay uses impedance aggregometry. A sample of 200 µL whole blood 
is positioned in a cuvette containing an electrode. When a reagent is supplemented to the 
cuvette the platelets activation and aggregation is induced, intensifying impedance (Figure 9). 
The changes are measured and presented numerically and graphically as a curve with the results 
displayed as Area Under the Curve in Ohm*min (AUC). Three different reagents were utilized; 
ARATEM where activation is accomplished with arachidonic acid, ADPTEM where activation 
is prompted with ADP, and TRAPTEM where activation is stimulated with TRAP.64 
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FIGURE 9. The ROTEM®platelet assay uses impedance aggregometry to evaluate platelet activation and 
aggregation, which intensifies impedance. The changes are measured and presented numerically and 
graphically as a curve with the results displayed as Area Under the Curve in Ohm*min (AUC). 
In parallel with ROTEM® and ROTEM®platelet blood counts were analyzed in a hematology 
instrument pocH-100i (Sysmex Corp., Norderstedt, Germany). 
3.2.8 Transfusions 
Platelet units were leucocyte reduced and irradiated and each unit consisted of 240-300 x 109/L 
platelets. The platelet units were kept in platelet additive solution up to seven days, at 22°C in 
a platelet incubator (Helmer Agitator; Fenwal Europe, Mont Saint Guibert, Belgium).  
Study I-II: Packed Red Blood Cells (PRBC) were transfused at an arterial hemoglobin of 70 
g/L during CPB and <80 g/L after CPB, except in patients with major ongoing hemorrhage; 
plasma was administered if >2 U of PRBC was given; and platelets were administered if 
bleeding was excessive and clots were absent after the reversal of heparin with protamine and 
directed by thromboelastographic tests.  
Study III: Decision regarding platelet transfusion was made by the attending surgeon and 
anesthesiologists and were based on the clinical condition without knowledge of ROTEM® or 
ROTEM®platelet results. 
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3.3 STUDY INTERVENTIONS 
Study I-II: After informed consent, consecutive adult patients (n=40, Study I; n=210, Study 
II) were randomized into two groups: control group and treatment group (HeProCalc group). 
Random assignment was managed using unmarked envelopes, each holding a protocol 
indicating HeProCalc or control group that the perfusionist in charge of the patient drew during 
preparations for the operation. Neither surgeons or anesthetists were blinded to group 
assignment in Study I, whereas they both were blinded in Study II. Patients randomized to the 
control group obtained the traditional dose of 400 International Units (IU) of heparin/kg body 
weight, where after an ACT analysis was performed 3 minutes later. An additional dose of 
heparin (2,500 to 10,000 IU) was given at the discretion of the perfusionist if the ACT was 
<480 seconds. Thereafter, ACT was analyzed every 30 minutes or more often if the ACT value 
was unstable. Additional doses of heparin were given at the discretion of the perfusionist. After 
CPB, protamine was administered according to the fixed protamine dose regimen, at a ratio of 
1.0 to 1.3 mg/100 IU of the first bolus dose of heparin, thereby allowing for additional 
protamine for reversal of additional heparin given during CPB. Patients randomized to the 
HeProCalc group, received heparin and protamine as suggested by the program as described 
above. In both groups, the last 50 mg of protamine was given after the residual heparin- 
containing blood from the CPB circuit had been administered. 
3.4 DATA COLLECTION 
Study I: During surgery, the lowest bladder temperature was registered and the number of 
transfused units of PRBC, plasma, or platelets per- and postoperatively were recorded. 
Intraoperative bleeding and postoperative blood loss from the surgical drains until the morning 
of postoperative day 1 were registered. Baseline ACT was collected before induction of 
anesthesia. HTC and ACT analyses were conducted at three time points: 3 minutes after 
protamine administration in the OR, 1, and 3 hours following arrival to the intensive care unit 
(ICU). 
Study II: Standard perioperative clinical data were registered including 12-hour postoperative 
bleeding volume and units of postoperative transfusions, heparin and protamine dosages, 
baseline ACT, ACT after initial heparin dose, nadir ACT during CPB, as well as ACT and 
HTC after protamine and one hour after surgery, respectively. Transfusions of any blood 
products were recorded during the ICU stay up to 48 hours postoperatively. 
Study III: The intra- and postoperative bleeding volume during the first 12 hours after surgery 
and number of transfusions during stay in OR and the ICU were recorded. Arterial blood 
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samples for ROTEM® and ROTEM®platelet were drawn in 2 four-mL citrate tubes BD 
Vacutainer™ (Becton, Dickinson and Company, Franklin Lake, NJ, USA) at 2 or 3 time points, 
before induction of anesthesia (T0), after protamine reversal (T1), and a 3rd sample was 
collected after CPB if platelets had been transfused (T2). All samples were analyzed within 2 
hours.  
3.5 ETHICS 
The studies of this thesis conform to the principles of the Helsinki Declaration and ethics 
approval has been obtained from the Regional Ethical Review Board in Stockholm (Study I: 
2013/849-31/2; Study II: 2015/2210; Study III: 2015/1788-31/2; Study IV: 2015/2151-
32). Individual patient consent was obtained in Study I-III.  
3.6 OUTCOME DEFINITIONS  
3.6.1 Primary outcome 
The primary outcome in Study I was the administered total dose of protamine. In Study II 
the primary outcome was postoperative bleeding within 12 hours after end of surgery. In 
Study III the primary outcome was to analyze if ROTEM®platelet could provide additional 
information to conventional ROTEM® analysis concerning platelet function. In Study IV the 
primary outcome included changes in demographic, procedural and clinical characteristics 
between the two time periods, 2006-2007 and 2008-2014.  
3.6.2 Secondary outcomes 
In Study I secondary outcomes were postoperative blood loss and heparin requirements. The 
secondary outcomes of Study II included transfusion rate, and heparin/protamine dosing. In 
Study III the secondary outcome was risk factors for platelet transfusion.   
3.6.3 Statistics  
Continuous variables were presented using means and standard deviations, and medians and 
25th and 75th percentiles, and frequencies and percentages were used for categorical variables. 
In Study I-III, as most variables were not normally distributed, continuous variables were 
compared using the Mann–Whitney U-test. The Wilcoxon rank test was used to test related 
samples. Student t-test was only used for parametric data in Study IV, after testing for 
normality with the Shapiro-Wilk test. If data were not normally distributed, the Mann–
Whitney test was applied. Categorical variables were compared with Fisher’s exact test. All 
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presented p-values were two-sided, and p<0.05 was set as the threshold for statistically 
significant findings.  
The following assumptions were used for estimation of power in  
Study I: From previous clinical experience, we anticipated a 150 mg difference in protamine 
doses between the control and the HeProCalc group. Assuming a power of 0.80 and a 
significance level of 0.001, a study population of 20 patients in each group was necessary. Stata 
version 13.1 (StataCorp LP, College Station, Texas, United States) and R version 3.0.1 (R 
Foundation for Statistical Computing, Vienna, Austria) were applied for statistical analysis. 
Study II: Based on the results from Study I, we estimated a significant difference in 
postoperative bleeding between the control and the treatment group. Assuming a power of 0.80 
and a significance level of 0.05, a population sample of 43 patients in each group was required.  
Study III: Founded on retrospective data we anticipated a need for platelet transfusion in 50 
% of the cases. Since platelet function was tested before (T0) and after initiation of CPB (T1), 
and after platelet administration (T2), if given, the patients functioned as their own controls 
with appropriate paired testing. Thus, a number >20 was judged sufficient to avoid type I 
(p<0.05) and type II error (>80% power).  
Study II-IV: All statistical analyses were performed with SPSS version 23 for Mac OS (IBM 
SPSS Statistics, NY, US) or with SPSS version 25 for Windows (IBM SPSS Statistics, NY, 
US). 
 

  
 
27 
 
4 RESULTS 
4.1 STUDY I 
Of 40 randomized patients, 3 patients were excluded from the final analysis; 2 patients were 
cooled below 34°C (exclusion criteria); and 1 patient because of initiation of extracorporeal 
membrane oxygenation after CPB (violence of protocol). Of the remaining 37 patients, 1 
patient in the control group was reoperated <24 hours postoperatively due to an arterial 
bleeding (leaking aortotomy suture). All ACT values were above 400 seconds during CPB. As 
depicted in Table 1, no significant demographic baseline differences could be detected 
between the two groups.  
 
TABLE 1. Baseline characteristics   
Control group  
(n = 19) 
HeProCalc  
(n = 18) 
P valuea 
Age, y, mean (SD) 63.9 (10.4) 69.0 (10.7) 0.132 
Median (Q1–Q3) 67 (52–73) 73 (59–78) 
 
Female sex 3 (16%) 5 (28%) 0.447 
Weight, kg, mean (SD) 80.0 (13.5) 77.7 (12.6) 0.927 
Median (Q1–Q3) 78 (71–85) 79.5 (70–87) 
 
Height, cm, mean (SD) 174 (8.0) 173 (8.5) 0.615 
Median (Q1–Q3) 174 (170–177) 173 (170–178) 
 
Body surface area, m2, mean (SD) 1.9 (0.2) 1.9 (0.2) 0.770 
Median (Q1–Q3) 1.9 (1.8–2.0) 1.9 (1.8–2.0) 
 
Estimated GFR, mL/min/1.73 m2, mean 
(SD) 
86 (33) 76 (27) 0.315 
Median (Q1–Q3) 78 (69–106) 76.5 (55–92) 
 
Hemoglobin, g/L, mean (SD) 135 (16) 131 (13) 0.513 
Median (Q1–Q3) 137 (121–148) 134 (127–139) 
 
Platelets, 109/L, mean (SD) 206 (58) 218 (56) 0.475 
Median (Q1–Q3) 201 (166–240) 214 (182–260) 
 
Prothrombin time, INR, mean (SD) 1.1 (0.2) 1.0 (0.1) 0.318 
Median (Q1–Q3) 1.0 (1.0–1.1) 1.0 (0.9–1.1) 
 
Baseline ACT, s, mean (SD) 143 (22) 138 (18) 0.378 
Median (Q1–Q3) 137 (133–153) 135 (129–144) 
 
Aspirin 12 (63%) 14 (78%) 0.476 
Warfarin 4 (21%) 0 0.105 
Procedure 
  
0.769 
CABG 6 (32%) 5 (28%) 
 
Aortic valve replacement 4 (21%) 6 (33%) 
 
Other 9 (47%) 7 (39%) 
 
Mean (standard deviation) and median (interquartile range) or number of patients and percentage, acompared with Mann-
Whitney U-test or Fisher’s exact test. Abbreviations: ACT, activated clotting time; CABG, coronary artery bypass grafting; 
GFR, glomerular filtration rate; INR, international normalized ratio; SD, standard deviation; Q1, 25th percentile; Q3, 75th 
percentile 
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Moreover, we did not find any significant differences in duration of surgery, duration of CPB, 
perioperative blood loss, and fluid balance, Table 2. 
TABLE 2. Perioperative data   
Control group (n = 19) HeProCalc (n = 18) P 
valuea 
Mean (SD)  Median           
(Q1–Q3)  
Mean (SD)  Median          
(Q1–Q3)  
 
Duration of surgery, 
min  
212 (82)  201 (145–277)  213 (61)  207 (170–264)  0.988  
Cardiopulmonary 
bypass time, min  
104 (49)  99 (72–119)  103 (35)  102 (81–112)  0.915  
Perioperative fluid 
balance, mL  
1,893 (957)  1,650           
(1,325–2,275)  
1,893 
(1,127)  
1,925        
(1,600–2,100)  
0.704  
Bleeding during 
surgery, mL  
556 (426)  450 (300–750)  485 (241)  500 (300–700)  0.927  
 Mean (standard deviation) and median (interquartile range), aCompared with Mann-Whitney U-test. SD, standard 
deviation; Q1, 25th percentile; Q3, 75th percentile 
 
 
4.1.1 Heparin 
We did not find significant differences in mean total dosage of heparin, including bolus- and 
iterated doses, between the HeProCalc group and the control group (43,300 ± 13,000 IU vs. 
40,500 ± 10,500 IU, p=0.359; Table 3.). 
TABLE 3. Heparin, protamine, and postoperative bleeding in Study I  
Control group (n = 19) HeProCalc (n = 18) P valuea 
Mean (SD)  Median (Q1–Q3)  Mean (SD)  Median (Q1–Q3)  
Heparin before CPB, 
IU x103 
33 (7.2)  31.2 (30–35)  31.2 (6.4)  30 (25–35)  0.436  
Heparin total, IU x103  40 (10.6)  37.5 (32.5–47.5)  43.3 (12.9)  41.2 (37.5–47.5)  0.359  
Protamine, mg  330 (61)  300 (300–350)  211 (56)  200 (200–250)  <0.001  
Postoperative 
bleedingb, mL  
649 (279)  595 (400–870)  480 (229)  440 (340–530)  0.074  
Mean (standard deviation) and median (interquartile range), aCompared with Mann-Whitney U-test. CPB, cardiopulmonary 
bypass; IU, international units; bOne patient in the control group was excluded from the analysis of postoperative blood loss 
because of reoperation for surgical bleeding. SD, standard deviation; Q1, 25th percentile; Q3, 75th percentile 
 
 
4.1.2 Protamine 
The mean total amount of protamine was significantly lower in the HeProCalc group (211 ± 
56 mg vs. 330 ± 61 mg, p <0.001; Table 3.). No significant differences were detected in ACT 
values before heparin administration or after protamine administration between the two groups 
(Figure 10). 
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FIGURE 10. Activated clotting time (ACT) as measured at 4 different time points in unheparinized blood in 
the HeProCalc group versus the control group in Study I. Baseline ACT was measured before the induction of 
anesthesia. Values depicted are mean (SEM). No statistically significant differences between the groups were 
detected at any of the time points (p >0.05).  
 
4.1.3 Additional Heparin, Activated Clotting Time, Bleeding, and 
 Transfusion Requirements 
Mean ACT after the initial bolus of heparin was 514 ± 138 seconds in the HeProCalc group 
against 621 ± 141 seconds in the control group (p=0.013). In the HeProCalc group, 4 patients 
did not reach an ACT value exceeding 400 seconds after the initial bolus of heparin, while in 
the control group, all patients achieved an ACT value above 400 seconds. To accomplish ACT 
>480 seconds before initiation of CPB, additional heparin was administered in 8 of the 18 
(44.4%) patients in the HeProCalc group versus in 2 of 19 (10.5%) in the control group. Mean 
postoperative blood loss presented no significant difference between the groups (480 ± 229 
mL vs. 649 ± 279 mL, p=0.074), after 1 patient in the control group had been excluded due to 
reoperation for surgical bleeding (Table 3). Table 4 and Figure 11 depict the number of blood 
products transfused intra- and postoperatively. 
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TABLE 4 Transfusion of blood products in Study I  
Control group (n =19) HeProCalc (n = 18) 
Intraoperatively (total number of units)  2 8 
Packed red blood cells  0 4 
Plasma  0 2 
Platelet concentrate  2 2 
Postoperatively (total number of units)  6 10 
Packed red blood cells  4 3 
Plasma  0 5 
Platelet concentrate  2 2 
 
 
FIGURE 11. Transfusion of blood products in the HeProCalc group and the control group in Study I.  
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4.2 STUDY II 
Twenty of the 210 randomly allocated patients were excluded from the analysis due to re-
exploration for localized surgical bleeding (n=9), violation of protocol (n=2), administration 
of aprotinin (n=3), or nadir body temperature <32 ̊C during CPB (n=6). Hence, the final 
analysis included 190 patients, with 93 patients in the HeProCalc group (49%) and 97 
patients in the control group (51%). Figure 12 illustrates the patient flow chart matching 
with the CONSORT (Consolidated Standards of Reporting Trials) statement.  
 
 
FIGURE 12. Patient flow chart according to the CONSORT statement. CPB, cardiopulmonary bypass in 
Study II.  
 
As presented in Table 5, no significant differences were detected in baseline characteristics, 
including age, body mass index, EuroSCORE (European System for Cardiac Operative Risk 
Evaluation) II, preoperative hemoglobin, and preoperative anticoagulation therapy between 
the two groups. All except two patients stopped taking new oral anticoagulants >4 days prior 
to surgery, and of the two patients, one stopped intake of new oral anticoagulants 3 days prior 
to surgery and the other patient 2 days before surgery. 
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TABLE 5. Baseline characteristics in Study II 
 Intervention group 
n = 93 (49) 
Control group 
n = 97 (51) 
P valuea 
Age, years          68 (60-72) 
65 ± 10.1 
68 (64-74) 
67 ± 9.7 
0.279 
Female gender 16 (17) 21 (22) 0.469 
Height, cm 175 (170-180) 
176 ± 8.0 
175 (169-181) 
175 ± 9.3) 
0.623 
Weight, kg 83 (75-92) 
84.3 ± 14 
85 (74-95) 
85.3 ± 16 
0.629 
BMI, kg/m2 27.0 (24.2-29.8) 
27.3 ± 4.3 
27.4 (24.6-30.1) 
28.0 ± 4.6 
0.486 
EuroSCORE II score 1.25 (0.91-1.96) 
1.89 ± 2.6 
1.44 (0.95-2.64) 
2.21 ± 2.1 
0.061 
Creatinine, mmol/L 86 (73-95) 
86.2 ± 23.4 
83 (73-95) 
85.5 ± 21 
0.744 
INR 1.0 (1.0-1.1) 
1.05 ± 0.17 
1.0 (1.0-1.1) 
1.05 ± 0.14 
0.541 
Aspirin 51 (54.8) 51 (53.1) 0.884 
Categorical variables are presented as n (%) and compared with the Fischer’s exact test. Continuous variables are presented 
as mean (standard deviation), median (25th/75th percentile), and acompared with the Mann-Whitney U-test. BMI body mass 
index; INR international normalized ratio, EuroSCORE, European System for Cardiac Operative Risk Evaluation 
Perioperative data are presented in Table 6. There were no significant differences in any of 
the variables, including type of surgical procedure, duration of CPB or surgery, nadir body 
temperature, and intraoperative bleeding between the 2 groups.  
 
TABLE 6. Perioperative data in Study II 
 Intervention 
group 
n = 93 (49) 
Control group 
n = 97 (51) 
P valuea 
Body temperature nadir, °C 35.8 (35.5-36.0) 
35.6 ± 0.7 
35.8 (35.0-36.0) 
35.5 ± 0.8 
0.381 
Duration of surgery, minutes 187 (167-218) 
195 ± 45.6 
205 (167-242) 
212 ± 64.1 
0.083 
CPB, minutes 96 (71-117) 
98 ± 33.7 
94 (75-128) 
105 ± 45.7 
0.576 
Aortic cross clamp, minutes 72 (53-89) 
73 ± 27.6 
70 (54-93) 
79 ± 36.3 
0.563 
Type of Surgical Procedure   0.311 
CABG 37 (40) 35 (36)   
Minimal invasive MV-repair 8 (8.6) 8 (8.2)   
Minimal invasive AVR 5 (5.4) 6 (6.2)   
MVR 4 (4.3) 0    
AVR 22 (24) 21 (22)   
CABG + AVR 4 (4.3) 12 (12)   
Replacement of ascending aorta + AVR 5 (5.4) 3 (3.1)   
Replacement of ascending aorta  1 (1.1) 2 (2.1)   
Other surgical procedures 7 (7.5) 10 (10.3)   
Categorical variables are presented as n (%) and compared with the Fischer’s exact test. Continuous variables are presented 
as mean (standard deviation), median (25th/75th percentile) and acompared with the Mann-Whitney U-test. AVR, aortic 
valve replacement; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; MV, mitral valve; MVR, mitral 
valve replacement 
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According to Table 7, the initial median dose of heparin was significantly lower in the 
HeProCalc group (32,500 IU; IQR 30,000-35,000) compared with the control group (35,000 
IU; IQR 30,000-37,500; p=0.025), while the median total heparin dose did not vary 
significantly between the HeProCalc group (40,000 IU; IQR 32,500-47,500) and the control 
group (42,500 IU; IQR 35,000-50,000; p=0.685). After the initial heparin dose no patient in 
either group had an ACT <350 seconds. None of the patients in the HeProCalc group had a 
nadir ACT value <400 seconds during CPB compared with 2 patients in the control group 
(320 and 398 s). Antithrombin was administered at a dose of 500 to 1,000 IU to four patients 
in the HeProCalc group during CPB when the anticipated heparin concentration, according 
to the HeProCalc program, surpassed 600 IU/kg, while antithrombin was not administered 
to any patient in the control group. 
TABLE 7. Heparin, Protamine and ACT measurement in Study II 
 Intervention group 
n = 93 (49) 
Control group 
n = 97 (51) 
P 
valuea 
Heparin initial dose, x103, IU  32.5 (30-35) 
32.4 ± 4.5 
35 (30-37.5) 
34.3 ± 6.3 
0.025 
Number of extra heparin doses pre-CPB 0 (0-0) 
2.5 ± 5.9 
0 (0-0) 
1.2 ± 2.7 
0.248 
Heparin total dose, x103 IU  40 (32.5-47.5) 
41.7 ± 11 
42.5 (35-50) 
42.6 ± 10 
0.685 
Number of extra heparin doses during CPB 1 (0.0-2.0) 
1.44 ± 1.2 
1 (0.0-2.0) 
0.99 ± 1.1 
0.007 
Protamine, mg 210 (190-240) 
216 ± 48 
350 (300-380) 
352 ± 64 
<0.001 
Ratio Protamine/initial heparin dose (mg/100 IU) 0.62 (0.54-0.68) 
0.62 ± 0.1 
1.00 (1.00-1.00) 
0.99 ± 0.1 
<0.001 
Ratio Protamine/Total heparin dose (mg/100 IU) 0.53 (0.47-0.57) 
0.52 ± 0.1 
0.86 (0.75-1.00) 
0.85 ± 0.1 
<0.001 
ACT pre-heparin, seconds 139 (132-151) 
140 ± 16 
144 (129-153) 
141 ± 19 
0.636 
ACT pre-CPB, seconds 549 (493-653) 
579 ± 129 
594 (493-712) 
630 ± 170 
0.095 
Number of patients with a nadir ACT <400 
seconds during CPB 
0 (0) 2 (2.1)  0.498 
Each patient’s average ACT during CPB, seconds  557 (523-630) 
589 ± 97.6 
566 (524-660) 
611 ± 122 
0.431 
Each patient’s median ACT during CPB, seconds 554 (520-596) 
575 ± 99 
549 (518-635) 
600 ± 124 
0.405 
ACT post protamine, seconds 127 (121-133) 
126 ± 12 
126 (121-133) 
128 ± 12 
0.538 
HTC post protamine, seconds 125 (117-133) 
126 ± 12 
128 (121-133) 
128 ± 11 
0.148 
ACT 1 hour after end of surgery, seconds 124 (111-134) 
122 ± 19 
123 (110-133) 
122 ± 15 
0.575 
HTC 1 hour after end of surgery, seconds 123 (109-130) 
119 ± 17 
123 (110-130) 
121 ± 16 
0.578 
Categorical variables are given as n (%) and compared with the Fischer’s exact test. Continuous variables are displayed as mean 
(standard deviation), and median (25th/75th percentile) and acompared with the Mann-Whitney U-test. ACT, activated clotting 
time; CPB, cardiopulmonary bypass; HTC, heparinase test cartridge; IU, international units. 
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The median protamine doses were 210 mg (IQR 190-240) and 350 mg (IQR 300-380) in the 
HeProCalc and control groups, respectively (p <0.001), giving a ratio of protamine/initial 
heparin dose of 0.62:1 (range 0.40-0.93) for the HeProCalc group and 1.0:1 for the control 
group (p <0.001). The ACT and HTC values did not disagree significantly between the two 
groups.  
TABLE 8. Hemoglobin, bleeding and transfusions in Study II 
 Intervention group 
n = 93 (49) 
Control group 
N = 97 (51) 
P valuea 
Preoperative hemoglobin, g/L 142 (129-148) 139 ± 14.4 141 (130-147) 138 ± 14 0.771 
Nadir postoperative hemoglobin, g/L 100 (88.5-111.5)100 ± 14 92 (87-103) 95 ± 14 0.015 
Preoperative hemoglobin –  
nadir postoperative hemoglobin, g/L 
40 (29-47.5) 39.1 ± 15 44 (34-53) 43.3 ± 14 0.058 
Intraoperative bleeding, mL 300 (200-500) 385 ± 244 400 (250-500) 510 ± 713 0.219 
Postoperative bleeding 12h, mL 320 (250-460) 355 ± 157 350 (250-450) 362 ± 156 0.754 
PRBC U, Intraoperatively 0 (0-0) 0.08 ± 0.5 0 (0-0) 0.25 ± 1.1 0.072 
PRBC U, Postoperatively 0 (0-0) 0.49 ± 1.7 0 (0-0) 0.35 ± 0.9 0.909 
Plasma U, Intraoperatively 0 (0-0) 0.00 ± 0.0 0 (0-0) 0.04 ± 0.3 0.498 
Plasma U, Postoperatively 0 (0-0) 0.00 ± 0.0 0 (0-0) 0.05 ± 0.3 0.121 
Platelets U, Intraoperatively 0 (0-0) 0.05 ± 0.2 0 (0-0) 0.14 ± 0.5 0.283 
Platelets U, Postoperatively 0 (0-0) 0.05 ± 0.3 0 (0-0) 0.02 ± 0.1 0.362 
Intraoperative number of transfused 
allogeneic blood products 
0 (0-0) 0.13 ± 0.6 0 (0-0) 0.43 ±1.7 0.044 
Postoperative number of transfused 
allogeneic blood products  
0 (0-0) 0.55 ± 1.7 0 (0-0) 0.42 ±1.0 0.901 
Total number of transfused allogeneic 
blood products 
0 (0-0) 0.68 (2.0) 0 (0-1.00) 0.86 (2.2) 0.181 
Any transfusion, number of patients 17 (18) 24 (25) 0.295 
UDPB    
Class 0 77 (83) 79 (81) 0.851 
Class 1 6 (6.5) 8 (8.2) 0.783 
Class 2 7 (7.5) 10 (10) 0.614 
Class 3 3 (3.2) 0 0.115 
Class 4 0 0 - 
BARC CABG-related bleeding class 4 0 0 - 
BART  0 0 - 
PLATO major bleeding 20 (22) 30 (31) 0.102 
Categorical variables are presented as n (%) and compared with the Fischer’s exact test. Continuous variables are presented as 
mean, standard deviation, and median (25th/75th percentile) and acompared with the Mann-Whitney U-test ACT, activated 
clotting time; BARC, bleeding academic research consortium; BART, the blood conservation using antifibrinolytics in a 
randomized trial; CPB, cardiopulmonary bypass; ICU, intensive care unit; HTC, heparinase test cartridges; PRBC, packed red 
blood cells; PLATO, platelet inhibition and patient outcomes; UDPB, universal definition for perioperative bleeding; U, units. 
Median postoperative blood loss during the first 12 hours was 320 mL (IQR 250-460) and 
350 mL (IQR 250-450) in the HeProCalc and the control groups, respectively (p=0.754, 
Table 8). Postoperative transfusion rate of PRBC units during the ICU stay was comparable 
in both groups, with 12.9% in the HeProCalc group and 12.4% in the control group (p=1.00). 
There were no significant differences in number of transfused blood products during the 48-
hour study period, aside from fewer transfused units intraoperatively in the HeProCalc group 
(p=0.044). The difference in median preoperative hemoglobin and nadir post-CPB 
hemoglobin values did not differ significantly between the two groups (p=0.058), with a 
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decrease of 40 g/L in the HeProCalc group and 44 g/L in the control group. However, the 
median nadir post-CPB hemoglobin concentration differed significantly between the two 
groups (p=0.015), with 100 g/L in the HeProCalc group and 92 g/L in the control group. 
Moreover, postoperative bleeding and transfusion rate did not differ significantly between 
the groups when classified concurring with the adapted definitions of Bleeding Academic 
Research Consortium (BARC), Blood Conservation Using Antifibrinolytics in Randomized 
Trial (BART), Platelet Inhibition and Patient Outcomes (PLATO), and Universal Definition 
of Perioperative Bleeding (UDPB (Table 8). 
 
4.3 STUDY III 
 
The included patients underwent combined surgical procedures (n=10), redo surgery (n=14), 
surgery requiring circulatory arrest (n=2) and other complicated cardiac surgery (n=2).  
 
TABLE 9. Baseline characteristics in Study III 
 Whole cohort 
 
(n = 23) 
Transfused 
patients 
(n = 10) 
Non-transfused 
Patients 
(n = 13) 
P value 
Clinical Parameters 
Age, years 62 (52/74) 60.5 (50/73) 63 (57/74) 0.436 
Female gender, % 7 (30) 4 (40) 3 (23) 0.650 
BMI, kg/m2 24 (22/28) 23 (22/26) 25 (23/28) 0.533 
EuroSCORE II 3.33 (2.30/7.47) 7 (3.34/10.4) 3 (1.85/3.33) 0.012 
Preoperative laboratory data 
Hemoglobin, g/L 123 (111/133) 124 (104/133) 123 (115/128) 0.964 
Hematocrit, % 36.4 (33.4/38.3) 36.6 (33.0/39.0) 36.4 (34.0/38.0) 0.867 
Creatinine, µmol/L 84 (68/109) 87 (73/129) 84 (68/105) 0.532 
eGFR 77 (57/116) 69 (61/108) 95 (57/116) 0.522 
Platelet count x 109/L 156 (140/186) 154 (148/177) 156 (140/186) 0.892 
INTEM CT, seconds (100-240) 157 (135/183) 150.5 (131/186) 164 (153/180) 0.573 
INTEM CFT, seconds (30-110) 70 (61/81) 63.5 (50/82) 72 (66/81) 0.256 
EXTEM CT, seconds (38-79) 61 (52/66) 62 (50/65) 57 (53/66) 0.681 
EXTEM CFT, seconds (34-159) 75 (64/84) 74.5 (55/83) 75 (66/85) 0.512 
EXTEM MCF, mm (50-72) 64 (62/67) 65.5 (63/69) 63 (62/64) 0.189 
FIBTEM MCF, mm (9-25) 16 (11/21) 20 (15/23) 15 (10/16) 0.050 
ARATEM, AUC (70-153) 62 (33/73) 55 (28/87) 65 (45/71) 0.843 
ADPTEM, AUC (56-139) 48 (39/68) 44 (37/68) 59 (48/64) 0.263 
TRAPTEM, AUC (61-156) 89 (76.8/111) 86.5 (75/102) 89 (81/114) 0.446 
Data are presented as median (25th/75th percentile) for continuous variables, and as frequency (percentage) for categorical 
variables. Continuous variables were tested with the Mann-Whitney Test and categorical variables with the Chi-Square test or 
Fisher’s exact test. ROTEM and ROTEM®platelet normal values are presented in brackets (as presented by manufacturer 
TEM Innovations, GmbH, Munich, Deutschland). BMI, body mass index; eGFR, estimated glomerular filtration rate; AUC, 
area under curve; CFT, clot formation time; CT, clotting time; MCF, maximum clot firmness. 
 
After exclusion of 5 patients (use of aprotinin, n=3; clopidogrel not stopped according to the 
study protocol, n=1; laboratory sample was by mistake not analyzed, n=1), results from 23 
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patients were comprised in the final analysis. Ten out of 23 (43%) patients were given platelet 
transfusion during surgery after end of CPB. We did not find significant differences between 
transfused and non-transfused patients in respect to age, body mass index (BMI), or laboratory 
findings, including ROTEM® and ROTEM®platelet prior to surgery, with the exception that 
the transfused group had a higher EuroSCORE II, Table 9. 
 
4.3.1 ROTEM® and ROTEM®platelet analyses after CPB and after 
 platelet transfusion 
 
For all patients, results from ROTEM®, ROTEM®platelet, hemoglobin, hematocrit, and 
platelet count differed significantly between T0 and T1, Table 10. 
 
TABLE 10. ROTEM® and ROTEM®platelet analyses after CPB and after platelet transfusion in Study III. 
Whole cohort (n = 23). 
 Before CPB 
(T0) 
After CPB 
(T1) 
P valuea 
Platelet count (x109) 156(140/186) 101(81/135) <0.001 
ROTEM® analyses    
INTEM CT, seconds (100-240) 157 (135/183) 197 (170/217) <0.001 
INTEM CFT, seconds (30-110) 70 (61/81) 108 (81/128) <0.001 
EXTEM CT, seconds (38-79) 61 (52/66) 85 (75/88) <0.001 
EXTEM CFT, seconds (34-159) 75 (64/84) 97 (77/121) <0.001 
EXTEM MCF, mm (50-72) 64 (62/67) 57 (54/61) <0.001 
FIBTEM MCF, mm (9-25) 16 (11/21) 11 (10/15) <0.001 
ROTEM®platelet analyses    
ARATEM, AUC (70-153) 62 (33/73) 15 (8/26) <0.001 
ADPTEM, AUC (56-139) 48 (39/68) 32 (20/42) <0.001 
TRAPTEM, AUC (61-156) 89 (77/111) 65 (49/86) <0.001 
Data are presented as median (25th/75th percentile). aThe variables were tested with the Wilcoxon test. ROTEM and 
ROTEM®platelet normal values are presented in brackets (as presented by manufacturer TEM Innovations, GmbH, 
Munich, Deutschland). AUC, area under curve; CPB, cardiopulmonary bypass; CFT, clot formation time; CT, clotting 
time; MCF, maximum clot firmness. 
 
Patients receiving platelets had a significantly augmented EXTEM CT compared with the 
non-transfused group after end of CPB and prior to platelet transfusion (T1, 88 and 76 
seconds, respectively, p=0.008). At T1, other ROTEM® parameters or platelet counts were 
not significantly different between the groups, and with the ROTEM®platelet assay a 
significant difference between the two groups was only detected with TRAP activation (51 vs. 
80 AUC, p=0.004), Figure 13 and Table 11.    
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TABLE 11.  Hematological variables at T1 (after heparin reversal with protamine and before platelet 
transfusion) in Study III 
 Patients receiving 
platelet transfusions 
(n=10) 
Patients not receiving 
platelet transfusions 
(n=13) 
 P valuea 
Hemoglobin, g/L 83·5 (76/91·8) 90 (88/98) 0·170 
Erythrocyte Volume Fraction 0·25 (0·22/0·27) 0·27 (0·29/0×3 0·335 
Platelet count (x109/L) 87·5 (77/121) 106 (81/137) 0·250 
ROTEM® analyses and normal values     
INTEM CFT, seconds (30-110) 101·5 (86/157) 108 (80/126) 0·726 
INTEM CT, seconds (100-240) 217 (169/247) 194 (173/209) 0·119 
EXTEM CT, seconds (38-79) 88 (80/94) 76 (71/85) 0·008 
EXTEM CFT, seconds (34-159) 101 (78·3/123) 89 (77/121) 0·704 
EXTEM MCF, mm (50-72) 58 (53·3/62·3) 55 (54/59) 0·473 
FIBTEM MCF, mm (9-25) 14 (10·8/17·8) 11 (9/12) 0·042 
ROTEM®platelet analyses and normal 
values  
   
ARATEM, AUC (70-153) 13·5 (8·8/26) 20 (6/26) 0·659 
ADPTEM, AUC (56-139) 22 (15/35·8) 39 (24/43) 0·097 
TRAPTEM, AUC (61-156) 50·5 (47/67) 80 (65/90) 0·004 
Data are presented as median (25th / 75th percentile) and compared with athe Mann-Whitney test. ROTEM and 
ROTEMplatelet normal values are presented in brackets (as presented by manufacturer  TEM Innovations, 
GmbH, Munich, Deutschland). AUC, Area Under Curve; CFT, Clot Formation Time; CT, Clotting Time; MCF, 
Maximum Clot Firmness 
 
FIGURE 13. In the ROTEM®platelet assay (Study III), a significant difference between the transfused and 
non-transfused patients was only seen at T1 with TRAPTEM activation (51 vs. 80 AUC, p=0.004).  
In patients receiving transfusion of platelets, ROTEM®platelet showed significantly superior 
results after transfusion (T2) versus before (T1) regarding TRAPTEM (p=0.008), but 
without significant changes concerning ADPTEM or ARATEM, Figure 14.  
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FIGURE 14. In patients receiving transfusion of platelets (Study III), 
ROTEM®platelet showed significantly superior results after transfusion (T2) versus 
before (T1) regarding TRAPTEM (p=0.008), but without significant changes 
concerning ADPTEM or ARATEM. 
 
As depicted in Table 12, ROTEM® results improved and platelet count augmented 
significantly after platelet transfusion (87.5 x 109/L compared with 139 x 109/L following 
transfusion, p=0.002). After heparin reversal, ACT returned to baseline both for transfused 
and non-transfused patients (130 vs. 123 seconds, p=0.213). 
 
TABLE 12. Platelet transfused patients in Study III (n = 10) 
 After CPB (T1) After transfusion of 
platelets (T2) 
P valuea 
Laboratory data 
Hemoglobin, g/L 83.5 (76/91.8) 84 (73.8/90.8) 0.236 
Erythrocyte Volume Fraction 0.25 (0.22/0.27) 0.25 (0.22/0.27) 0.221 
Platelet count (x109/L) 87.5 (77.2/121) 139 (124/173) 0.002 
ROTEM® analyses 
INTEM CFT, seconds (30-110) 101.5 (86/157) 73 (63.3/85.5) 0.002 
INTEM CT, seconds (100-240) 217 (169/247) 199.5 (161/207) 0.127 
EXTEM CT, seconds (38-79) 88 (80.5/94) 64 (59/66.5) 0.002 
EXTEM CFT, seconds (34-159) 100.5 (78.3/123) 71.5 (61.8/82) 0.002 
EXTEM MCF, mm (50-72) 58 (53.3/62.3) 66.5 (61.8/68.8) 0.004 
FIBTEM MCF, mm (9-25) 14 (10.8/17.8) 19.5 (14.3/24.8) 0.004 
ROTEM®platelet analyses 
ARATEM, AUC (70-153) 13.5 (8.8/26) 28.5 (4.5/70.8) 0.191 
ADPTEM, AUC (56-139) 22 (15.8/35.8) 25.5(18.5/50) 0.141 
TRAPTEM, AUC (61-156) 50.5 (47/67) 72 (53.8/79) 0.008 
Data are presented as median (25th/75th percentile). aThe variables were tested with the Wilcoxon test. ROTEM and 
ROTEM®platelet normal values are presented in brackets (as presented by manufacturer TEM Innovations, GmbH, 
Munich, Deutschland). AUC, area under curve; CPB, cardiopulmonary bypass; CFT, clot formation time; CT, clotting 
time; MCF, maximum clot firmness 
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4.3.2 Risk factors for transfusion 
Patients given platelet transfusion had, in addition to a preoperatively elevated EuroSCORE II 
(7 vs. 3, p=0.012), significantly prolonged duration of surgery (290 vs. 254 minutes, p=0.034) 
and significantly lengthier time on CPB than patients in the non-transfused group (192.5 vs. 
117 minutes, p=0.005). Also, intraoperative blood loss was significantly elevated in patients 
receiving platelet transfusions (850 vs. 600 ml, p=0.002). Concerning the 12-hour 
postoperative bleeding volume, no significant difference was found between transfused and 
non-transfused patients, Table 13. Five of the transfused patients received 1 unit of platelets 
and 5 patients received 2 units. No adverse outcomes related to the transfusions were detected. 
Of the 10 patients receiving platelet transfusion, only 4 received PRBC (range 1-4 units) and/or 
plasma (range 1-2 units), and all 10 were administered fibrinogen (range 1-5 g) during the 
perioperative procedure.  
 
TABLE 13. Peri- and postoperative parameters in Study III 
 Whole 
cohort 
(n = 23) 
Transfused patients 
(n = 10) 
Non-transfused 
patients (n = 13) 
P valuea 
Duration of surgery, minutes 276 (230/333) 290 (270/436) 254 (214/286) 0.034 
CPB, minutes               135 (110/203) 192.5 (147/284) 117 (110/131) 0.005 
Intraoperative bleeding, mL 700 (450/900) 850 (800/1800) 600 (400/700) 0.002 
12 h postoperative bleeding, mL 410 (270/710) 510 (270/860) 410 (320/620) 0.594 
PRBC, Units intraoperatively 0 (0/2) 0 (0/2) 0 (0/0) 0·256 
Plasma, Units  intraoperatively 0 (0/0) 0 (0/0) 0 (0/0) 0·435 
Fibrinogen, grams 
intraoperatively 
2 (2/4) 3 (2/4) 2 (0/4) 0·085 
PCC, IU intraoperatively 0 (0/125) 0 (0/0) 0 (0/0) 1·000 
Platelets, Units  intraoperatively 0 (0/1) 1 (1/2) 0 (0/0) <0·001 
Data are presented as median (25th/75th percentile) and compared with athe Mann-Whitney test. CPB, cardio 
pulmonary bypass. U, International Units; PCC, Prothrombin complex concentrate. 
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4.4 STUDY IV 
 
Between 2006 and 2014, 268 patients underwent isolated CABG surgery (not including redo 
and combined procedures) and obtained aprotinin. Administration of aprotinin diminished 
considerably after 2007: 226 patients received the drug in 2006‒2007 (mean 113 
patients/year) versus 42 in 2008‒2014 (mean 6 patients/year). Demographics and procedural 
characteristics are described in Table 14. 
 
 
TABLE 14. Demographics in Study IV 
 CABG patients 
receiving 
aprotinin, 2006-
2014 (n = 268) 
CABG patients 
receiving 
aprotinin, 2006-
2007 (n = 226) 
CABG patients 
receiving 
aprotinin, 2008‒
2014 (n = 42) 
P value 
Age 65.5 ± 9.8 65.2 ± 9.7 66.9 ± 10.1 0.32 
Male gender 212 (79%) 181 (80%) 31 (74%)  
Size (cm) 173.5 ± 10.3 173.5 ± 10.5 173.9 ± 9.6 0.83 
Weight (kg) 82.7 ± 15.9 82.4 ± 15.9 84.2 ± 16.0 0.52 
Body surface area (m2) 2.0 ± 0.2 2.0 ± 0.2 2.0 ± 0.2 0.49 
Higgins risk score 0.026 ± 0.058 0.022 ± 0.046 0.046 ± 0.10 0.134* 
EuroSCORE I (additive) 4.9 ± 3.4 4.6 ± 3.1 7.1 ± 4.8 0.009 
EuroSCORE I 
 (logistic) 
6.0 ± 9.6 5.1 ± 6.6 13.4 ± 20.7 0.039* 
EuroSCORE II (logistic) 5.5 ± 8.4 N/A 5.5 ± 8.4 N/A 
Procedural characteristics     
CPB (min) 65.1 ± 26.9 63.6 ± 24.4 73.2 ± 37.1 0.032 
Cross-clamp (min) 39.0 ± 18.1 38.8 ± 19.0 39.6 ± 11.7 0.8 
Ventilator time (h) 10.1 ± 32.4 9.3 ± 27.8 13.8 ± 48.5 0.44 
Laboratory data     
Albumin (g/L) 36.4 ± 3.7 36.5 ± 3.5 36.0 ± 4.7 0.48* 
Creatinine (µmol/L) 94.0 ± 56.3 92.9 ± 49.9 100.0 ± 83.1 0.46 
Creatinine clearance 
(mL/min)† 
75.5 ± 24.3 75.8 ± 24.7 73.8 ± 22.5 0.63 
Data are expressed as numbers (percentage) for categorical variables, or as mean ± SD, *Calculated with non-parametric test; 
†Estimated using the Cockcroft-Gault equation. CPB, cardio pulmonary bypass, CABG, coronary artery bypass grafting. 
 
 
 
Generally, patient demographics were comparable for both time periods. Nevertheless, mean 
EuroSCORE I and average CPB duration were higher during the second period, reflecting 
both an enlarged operative risk and an increased risk of bleeding. Clinical outcomes and 
postoperative laboratory data are shown in Table 15.  
 
 
 
  
 
41 
TABLE 15. Clinical outcomes in Study IV 
 CABG patients 
receiving 
aprotinin, 2006-
2014 (n = 268) 
CABG patients 
receiving 
aprotinin, 2006-
2007 (n = 226) 
CABG patients 
receiving 
aprotinin, 2008-
2014 (n = 42) 
P 
value 
Extracorporeal membrane 
oxygenation 
4 (1%) 1 (0.4%) 3 (7.1%) 0.013 
Intra-aortic balloon pump 10 (4%) 6 (2.7%) 4 (9.5%) 0.054 
ICU stay (days) 1.95 ± 2.9 1.88 ± 2.86 2.31 ± 2.85 0.37 
30-day mortality 17 (6.3%) 12 (5.3%) 5 (11.9%) 0.157 
1-year mortality# 26 (9.7%) 21 (9.3%) 5 (11.9%) 0.574 
Stroke 3 (1.1%) 2 (0.9%) 1 (2.4%) 0.40 
Multi-organ failure 19 (7.1%) 13 (5.8%) 6 (14.3%) 0.092 
Intraoperative blood loss (mL) 628 ± 819 591 ± 643 846 ± 1469 0.298* 
Total postoperative blood loss (mL) 628 ± 455 631 ± 467 604 ± 380 0.741 
Reoperation for bleeding 22 (8.2%) 18 (8.0%) 4 (9.5%) 0.760 
PRBC within 48 h (U) 1.7 ± 3.9 1.44 ± 2.92 3.14 ± 6.90 0.123* 
Plasma within 48 h (U) 1.3 ± 4.4 0.92 ± 2.67 3.33 ± 8.98 0.092* 
Platelets within 48 h (U) 0.36 ± 0.79 0.31 ± 0.72 0.62 ± 1.08 0.081* 
PRBC >48 h to discharge (U) 1.3 ± 4.0 1.27 ± 3.69 1.17 ± 5.43 0.88 
Plasma >48 h to discharge (U) 0.62 ± 3.5 0.52 ± 2.62 1.17 ± 6.42 0.52* 
Platelets >48 h to discharge (U) 0.04 ± 0.48 0.02 ± 0.33 0.17 ± 0.94 0.33* 
Postoperative laboratory data     
ASAT on day 1 (IU/L) 2.0 ± 8.9 2.07 ± 9.65 1.68 ± 2.89 0.80 
ALAT on day 1 (IU/L) 0.87 ± 1.0 0.93 ± 1.08 0.58 ± 0.61 0.052 
CK-MB on day 1 (IU/L) 32.1 ± 82.8 29.9 ± 55.9 55.2 ± 159 0.33* 
Creatinine on day 1 (µmol/L) 91.4 ± 44.3 90.6 ± 46.5 95.5 ± 29.7 0.52 
Creatinine clearance on day 1 
(mL/min)† 
92.9 ± 33.1 94.1 ± 33.4 85.8 ± 30.9 0.14 
Δ creatinine clearance (day 0 ‒ day 1 
(mL/min)† 
17.2 ± 18.6 18.4 ± 18.0 10.5 ± 20.6 0.012 
Data are expressed as numbers (percentage) for categorical variables, or as mean ± SD.*Calculated with non-parametric 
test; †Estimated using the Cockcroft-Gault equation; #Available for all but 1 patient. Abbreviations: ALAT, alanine 
transaminase; ASAT, aspartate aminotransferase; CK-MB, creatine phosphokinase-MB; PRBC, pack red blood cell 
transfusion, CABG, coronary artery bypass grafting. 
 
There were no significant differences between the 2 periods regarding postoperative 
mortality, postoperative complications, intra- and postoperative bleeding, and transfusion 
rates. More patients needed extracorporeal membrane oxygenation (ECMO) during the 2nd 
period (7.1% versus 0.4%; p=0.013), which may be related to the increased operative risk in 
the 2nd group and to the more frequent use of ECMO during this period. The increase in 
creatinine clearance from day 0 to day 1 was lesser during the 2nd period (10.5 ± 20.6 versus 
18.4 ± 18.0; p=0.012 
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5 DISCUSSION 
The main findings of this thesis were as follows. A small pilot RCT using the HeProCalc 
computer program indicated a significant reduction in protamine used for heparin reversal after 
CPB, without prolongations of ACT, compared with a control group, where the protamine 
dose was administered according to body weight. Furthermore, the HeProCalc-based 
algorithm was associated with less postoperative bleeding. In a subsequent large RCT the 
HeProCalc guiding reduced protamine dosage and protamine/heparin ratio after CPB 
compared with traditional dosage by weight, without significantly reducing postoperative 
blood loss or transfusion rate. Moreover, in a small observational study, platelet transfusion 
after CPB significantly improved response to thrombin activation, measured with 
ROTEM®platelet TRAPTEM, indicating that CPB induced platelet dysfunction may be 
reversed by platelet transfusion. Finally, a retrospective clinical study showed that CABG 
patients on DAPT with platelet aggregation <85% on day of surgery receiving aprotinin 
between 2008 and 2014 did not have significantly different clinical outcomes or transfusion 
rates compared to those patients receiving aprotinin during the prior two years, despite a 
significantly higher operative risk and a longer mean CPB time. 
5.1 HEPROCALC GUIDANCE VS. STANDARD HEPARIN/PROTAMINE 
DOSAGE  
The use of heparin influences hemostasis after CPB and the specific antidote protamine 
reverses the anticoagulant effect of heparin. Different methods are used to calculate the 
appropriate heparin dosing, including heparin dose response (HMS Plus Hemostasis 
Management System, Medtronic, Minneapolis, MN, USA) or dosage based on body weight, 
gender and pump priming volume.65 HMS Plus System uses heparin titration assays to 
estimate the initial heparin dose, dosing during CPB, and needed dose of protamine for 
reversal of the heparin after CPB.66, 67 The system uses channels with different amount of 
protamine and the channel containing the dose of protamine resulting in the shortest ACT 
decides the protamine dose for reversal of heparin. However, the HMS Plus system has 
disadvantages including high costs and a tendency to underestimate the initial dose response 
of heparin.68 Aiming for a specific heparin concentration is difficult as blood volume during 
CPB tends to change during CPB and fluid may be redistributed. Furthermore, the response 
to heparin varies considerably between patients and is also influenced by ATIII levels. 
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5.1.1 Heparin dosing 
Traditionally and the most commonly (75%) used method worldwide is to calculate heparin 
dosage for CPB based on body weight,42 resulting in the majority of centers in initial doses 
of heparin between 300 and 400 IU/kg.42 Likewise, most international centers (88%) 
maintain anticoagulation during CPB via additional heparin dosed to target ACT, and only 
7% of centers administer additional heparin to maintain heparin level, e.g. HMS Plus 
System.42 According to the STS/SCA/AmSECT guidelines “use of heparin concentration in 
addition to ACT might be considered for the maintenance of CPB” (Level IIb, Evidence B, 
Table 15).44  
The heparin effect is usually reversed with a protamine dose of 1.0-1.3 mg per 100 IU (1 
mg) of heparin7 given and is assumed to neutralize heparin’s anticoagulant effect. Excessive 
protamine possibly increases further bleeding by weakening platelet function, 
downregulating thrombin generation, and diminishing clot structure.39, 40 Still, in cardiac 
surgery with CPB, protamine reversal is inevitable after full heparinization. Traditional 
dosing of heparin and protamine may be put in question, and several studies have attempted 
to define the ideal ACT level for CPB, where a minimum value of 400-480 seconds is mostly 
used.42 However, latest guidelines recommend a minimal ACT level of 480 seconds during 
CPB (Level IIa, Evidence C, Table 16).44 An ACT between 500 and 700 seconds during 
CPB is associated with less postoperative bleeding compared with when ACT levels < 500 
or > 700 seconds are used.69 The increased postoperative bleeding associated with an ACT 
< 500 seconds during CPB may be explained by augmented consumption of coagulation 
factors, while excessive heparin dosage with ACT > 700 seconds may amplify the risk of 
post-CPB bleeding after protamine reversal due to possible heparin rebound.69  
In Study I, additional heparin doses were more frequently given in the HeProCalc group 
compared with the control group to achieve acceptable ACT values before start of CPB. This 
possible disadvantage must be balanced against the risk of excessive heparin dosing.  
In contrast to the small Study I, the initial dose of heparin in the larger Study II given to 
HeProCalc group was slightly but significantly less than that administered to the control group 
(400 IU/kg) (p=0.025), although in both groups median ACT after initial heparin dosage was 
considerably above 500 seconds, without differing significantly (Table 7) p=0.095). However, 
none of the patients in the HeProCalc group and the control group had an ACT value <400 
and <320 seconds, respectively. This is in distinct contrast to the study by Garvin et al.,68 where 
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the 300 seconds ACT-level was missed in 7.4% of patients and the 350 seconds level was 
missed in 16.9% of patients using the HMS Plus System. 
In Study II, the total heparin dose did not differ significantly between the two groups, but 
heparin was administered significantly more frequently in the HeProCalc group during CPB. 
This probably was a result of the perfusionist responding to the HeProCalc system, which 
displays when the estimated ACT is close to fall below 480 seconds. Also, the more repeated 
dosing of heparin may clarify why none of the patients in the HeProCalc group versus two 
patients (2.1%) in the control group had nadir ACT levels below 400 seconds during CPB. 
Furthermore, four patients (4.1%) in the HeProCalc group received additional ATIII because 
of the close monitoring with the HeProCalc system. A summary of the different guidelines 
regarding heparin dosing, ATIII dosing and ACT levels are presented in Table 16 and Table 
17, respectively. 
TABLE 16.  International guidelines for heparin dosing. 
HEPARIN DOSING 
Class,  
Level 
 of  
evidence 
2011 STS/SCS 
Blood conservation 
clinical practice 
guidelines70                                   
In patients requiring longer CPB times (>2 to 3 hours), maintenance of 
higher and/or patient-specific heparin concentrations during CPB may be 
considered to reduce hemostatic system activation, reduce consumption 
of platelets and coagulation proteins, and to reduce blood transfusions. 
IIb, B 
2017 
EACTS/EACTA 
Guidelines patient 
blood 
management21                          
Heparin level-guided heparin management should be considered over 
ACT-guided heparin management to reduce bleeding 
IIa, B 
2018 STS/SCS/ 
AmSECT Clinical 
Practice 
Guidelines-
Anticoagulation 
During 
Cardiopulmonary 
Bypass44 
Bolus administration of unfractionated heparin based on weight is 
reasonable for achieving adequate anticoagulation, but individual 
response to heparin is heterogeneous and requires a therapeutic functional 
test of clot inhibition before initiation of CPB, independent of the bolus 
dose used. 
IIa, C 
Use of a heparin dose-response formula may identify reduced sensitivity 
to heparin but has not been shown to be more useful than weight-based 
heparin dosing in determining the heparin dose required to achieve an 
adequate ACT for initiation of CPB. 
IIb, B 
Use of heparin concentration monitoring in addition to ACT might be 
considered for the maintenance of CPB, as this strategy has been 
associated with a significant reduction in thrombin generation, 
fibrinolysis, and neutrophil activation. However, its effects on 
postoperative bleeding and blood transfusion are inconsistent. 
IIb, B 
During CPB, routine administration of unfractionated heparin at fixed 
intervals, with ACT monitoring, might be considered and offers a safe 
alternative to heparin concentration monitoring.  
IIb, C 
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TABLE 17. International Guidelines regarding ATIII dosing and ACT levels. 
ATIII MANAGEMENT Class, 
Level of 
evidence 
ACT LEVEL Class, 
Level of 
evidence 
2011 STS/SCS 
Blood conservation 
clinical practice 
guidelines70                                   
Antithrombin III (AT) 
concentrates are indicated to 
reduce plasma transfusion in 
patients with AT mediated 
heparin resistance* immediately 
before cardiopulmonary bypass. 
I, A No Guidelines  
2017 
EACTS/EACTA 
Guidelines patient 
blood 
management21                          
AT supplementation is indicated 
in patients with AT deficiency to 
improve heparin sensitivity. 
I, B No Guidelines  
 
2018 STS/SCS/ 
AmSECT Clinical 
Practice 
Guidelines-
Anticoagulation 
During 
Cardiopulmonary 
Bypass44 
No Guidelines  It is reasonable to 
maintain ACT above 
480 seconds during 
CPB. For instruments 
using “maximal 
activation” of whole 
blood or 
microcuvette 
technology, values 
above 400 seconds. 
are frequently 
considered 
therapeutic 
A functional whole 
blood test of 
anticoagulation, in 
the form of a clotting 
time, should be 
measured and should 
demonstrate adequate 
anticoagulation 
before initiating and 
at regular intervals 
during CPB. 
IIa, C 
 
 
 
 
 
 
 
 
 
 
 
 
I, C 
*Heparin resistance is defined as the failure to achieve activated clotting time of at least 400 s to 480 s after 
a standard heparin dose, although there is a substantial variability in the definition of the “standard” heparin 
dose, ranging from less than 400 to 1,200 U/kg  
  
5.1.2 Protamine dosing 
Earlier reports have indicated that a lower dose of protamine than the traditional 1:1 weight 
based ratio used may be sufficient to completely reverse the heparin effect.65, 71-73 Even if 
protamine is an antidote to heparin, it is not a procoagulant and it may in fact have 
anticoagulant effects by itself.7 Excessive amounts of protamine may according to reports 
increase ACT values.39, 44 When reversal of heparin is based on titration, the protamine dose 
intends to match the circulating amount of heparin. Indeed, heparin/protamine titration with 
heparin concentration management may lower the protamine/heparin ratio without 
augmented postoperative bleeding.65, 74, 75  
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The HeProCalc algorithm suggests time and dosage of heparin during CPB as the program 
also considers the level of hemodilution (volume of prime), CPB duration, and current 
temperature when continuously displaying calculated ACT and calculated remaining amount 
of body heparin. Besides, after CPB weaning the HeProCalc program estimates the individual 
protamine dose required for heparin neutralization based on the calculated remaining amount 
of body heparin.  
To our knowledge there are three other models for protamine dosage after CPB, although not 
for heparin. First, the statistical model, developed by Davidsson et al.72 includes body surface 
area, preoperative platelet count and heparin clearance along with total amount of heparin to 
calculate protamine dosage for heparin reversal, resulting in a protamine/total heparin ratio of 
0.51:1. Second, a pharmacokinetic model for protamine dosage, based on heparin elimination, 
resulted in a protamine/total heparin ratio of 0.5:1.71 Third, Suarez et al.76 developed a 
mathematical model for protamine dosage, which resulted in a protamine/heparin dosage ratio 
to the initial and to the total heparin dosage of 0.96:1 and 0.60:1, respectively.  
The results of Study I, a small RCT, are consistent with earlier studies, and suggest that 
lower protamine doses than conventionally given, do not exacerbate postoperative blood 
loss. Conversely, in Study I there was a trend to less postoperative bleeding in the 
HeProCalc group compared with the control group, even if 36% less protamine was given 
in this group. Both groups in Study I received equal total amounts of heparin.  
In Study I, a significantly lower dose of protamine was given in the HeProCalc group despite 
similar total heparin dosages in both groups. Postoperative ACT values did not vary much 
between the groups (Figure 10). Moreover, parallel HTC measuring with heparinase did not 
indicate that the slight postoperative ACT increase in both groups could be related to 
remaining heparin. Study I support previous studies77-79 that recommend a low-dose 
protamine regime to avoid possible disadvantages with the drug. A ratio of >1.0 between 
total protamine and total intraoperative heparin has been associated with an increased risk 
(odds ratio 3.4, 95% confidence interval 2.4-4.9; p <0.001) of transfusion and postoperative 
blood loss.41 Furthermore, the STS/SCA/AmSECT guidelines state that one should consider 
protamine titration44, 70 (Table 18) and to limit the administered heparin/protamine weight 
ratio (e.g. 50% of total heparin dose)70 to <2.644 to avoid excessive postoperative bleeding. 
However, the 2017 EACTS/EACTA guidelines recommend a protamine/initial heparin ratio 
of <1:1 to reduce post-CPB bleeding (Level IIb, Level B) and to limit protamine dosage, 
preferably by using a titration method (Level IIb, Level B).21 
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TABLE 18. International guidelines regarding protamine dosing. 
PROTAMIN DOSING Class,  
Level of  
evidence 
2011 STS/SCS Blood 
conservation clinical 
practice guidelines70 
 
Use either protamine titration or empiric low dose regimens 
(e.g., 50% of total heparin dose) to lower the total protamine 
dose and lower the protamine/heparin ratio at the end of CPB 
may be considered to reduce bleeding and blood transfusion 
requirements. 
IIb, B 
2017 EACTS/EACTA 
Guidelines patient blood 
management21 
 
 
The dose of protamine is usually based on the initial or total 
administered dose of heparin throughout the procedure. 
IIb, B 
Heparin level-guided protamine dosing may be considered to 
reduce bleeding and transfusions. 
IIa, B 
Protamine should be administered in a protamine-to heparin 
dosing ratio <1:1 to reduce bleeding. 
IIa, B 
2018 STS/SCS/ 
AmSECT Clinical 
Practice Guidelines-
Anticoagulation During 
Cardiopulmonary 
Bypass44 
It can be beneficial to calculate the protamine reversal dose 
based on a titration to existing heparin in the blood, since this 
technique has been associated with reduced bleeding and 
blood transfusion. 
IIa, B 
It is reasonable to limit the ratio of protamine/heparin to less 
than 2.6 mg protamine /100 units heparin because total doses 
above this ratio inhibit platelet function, prolong ACT, and 
increase the risk of bleeding. 
IIa, C 
In Study II the initial heparin dosing according the HeProCalc algorithm was not apparently 
different from 400 IU/kg in the control group, and the protamine dose was about 0.6 times 
the initial heparin bolus. This raises the question why to use the HeProCalc algorithm when 
it can be calculated much easier? However, the median ratio protamine/initial heparin dose 
(mg/100 IU) was 0.62 (25th/75th percentile 0.54-0.68), according to Table 7 and the range 
was 0.40–0.93 in the intervention group. Thus, the variation in ratio between patients was 
rather high (0.53). This would not have been possible with a fixed ratio. 
5.1.3 Postoperative bleeding 
In the small Study I, mean postoperative blood loss did not differ significantly between the 
HeProCalc and the placebo group, with 480 mL and 649 mL, respectively (p=0.074). First, 
it was assuring that Study I did not indicate increased postoperative bleeding in the 
HeProCalc group compared with the control. Second, the non-significant difference initiated 
us to conduct the larger Study II to better assess possible impact on postoperative bleeding. 
Although the mean difference of approximately 200 mL may seem small when deciding 
whether to transfuse or not, it may be the tipping point for some patients. Furthermore, any 
measures that decrease transfusion rate may be considered as vital, because transfusions have 
been associated with morbidity and mortality,1-6. Additionally, the number of patients in 
Study I was too low to study effects of transfusion rates. Again, this was another reason for 
us to conduct Study II to better clarify if the HeProCalc algorithm may significantly 
influence postoperative transfusion rates.  
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The cause of bleeding after CPB is multi-factorial and bleeding itself may promote further 
bleeding unless properly treated. A lack of protamine as a cause of bleeding may be ruled 
out, for example, with HTC testing. Improved treatment of postoperative bleeding may be 
achieved with additional POC analyses, e.g. thromboelastography and platelet function 
testing, as the HTC test is specific for heparin and thus will not indicate other explanations 
for a prolonged ACT. 
The relatively high protamine reversal dose for heparin at a ratio to 1:1 has a negative impact 
on coagulation, including prolonged clotting time according to thromboelastography,43, 71 
platelet dysfunction, and inhibition of factor V activation with an resulting prolonged bleeding 
time.40, 80 This has motivated several groups to investigate reduced ratios.71-73, 76 In Study II, 
the reversal ratio in the HeProCalc group was 0.62:1 (median and mean) compared with 1:1 
to the initial heparin dose in the control group. This corresponds, when using total instead of 
initial heparin dose, to a median and a mean ratio of 0.53 and 0.52, respectively, in the 
HeProCalc group compared with 0.86 and 0.85, respectively, in the control group. The total 
ratio in the HeProCalc group was equal or similar to those in other RCTs using the HMS Plus 
system, including Vonk et al. (total ratio 1:0.62),67 Hofmann et al. (total ratio 1:0.67),75 and 
Hoenicka et al. (total ratio 1:0.54).66 Moreover, the total ratio was comparable to the statistical 
protamine reversal algorithm, tested by Davidsson et al.72(total ratio 1:0.51), which is based 
on results with the HMS Plus system. In Study II the capability of the reduced protamine dose 
to sufficiently reverse blood heparin was proven by additional heparinase testing (HTC) 3 
minutes after protamine reversal and 1 hour after end of surgery (Table 7). This coincides with 
the results of the earlier mentioned studies, which, however, using different criteria to verify 
sufficient reversal. Specifically, in Study I-II we used the HTC/ACT to show if heparin was 
completely reversed or not as this is standard technique at our center to detect possible residual 
heparin. This assay is a rather "rough" test. Within the context of a clinical study, the use of an 
anti-Xa test would have been preferable. In addition, the complete reversal of heparin is only 
one side of the medal. The other question is, whether the protamine dose calculated by the 
HeProCalc algorithm perfectly matched the real protamine demand or still was excessive. In 
this regard it would have been interesting to compare the protamine demand calculated by the 
device with the reference method of the HMS Plus system. There are number of other ways to 
verify complete reversal of heparin including delta ACT71, ACT<140 sec after protamine 
administration76, return to baseline ACT ± 10%,66 ACT ratio was greater than 1.173 or heparin- 
protamine titration (HMS Plus system)67, as well as the anti-Xa-test. 
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Motivated by the tendency of less postoperative blood loss (p=0.074) with the HeProCalc 
system in Study I (n=40), according to a power analysis, 86 patients were found to be needed 
for Study II regarding bleeding and possibly also transfusions. However, despite including 
190 patients in Study II, we did not find that the HeProCalc system had a significant effect on 
postoperative bleeding volume or transfusion rate. Interestingly, we found that the nadir 
postoperative hemoglobin concentration was significantly lower in the control group 
(p=0.015), while the difference between preoperative and nadir postoperative hemoglobin 
concentrations was merely close to being significantly lower in the HeProCalc group 
(p=0.058). Besides, the total number of transfused units was lower in the intervention group 
(p=0.181). It may be argued whether these nonsignificant results regarding postoperative 
blood loss and transfusion rate are explained by a type II error or not. Nevertheless, the low 
median 12-hour postoperative blood loss of 320 ml and 350 mL in the HeProCalc and the 
control group, respectively, and the low rate of patients receiving transfusions, 18.3% and 
24.7%, respectively, may hint in this direction. Other reports with low protamine ratios have 
presented conflicting results. The large RCT (n=200) by Koster et al.81 using the HMS Plus 
system in their intervention group likewise founds a nonsignificant decrease in 12-hour 
postoperative bleeding volume, and Vonk et al.67(n=38) reported significantly lower blood loss 
(<450 mL 24 h postoperatively) with the HMS Plus system. On the other hand, Slight et al.82 
(n=38) found increased 12-hour bleeding volume (p=0.06) with the HMS Plus system, 
comparable to Hoenicka et al.66 (n=120), who reported that postoperative blood loss was 
significantly increased at 12 hours (p=0.004) but not at 24 hours (p=0.11). Additionally, the 
meta-analysis of 4 RCTs81, 83-85 by Wang et al.86 advocated “that titrated protamine dosing is 
more effective than standard protamine dosing for alleviating postoperative bleeding after 
CPB.” Thus, Study II and previous similar reports may have included too few patients, and 
we support with the recent call from the Task Force on Patient Blood for Adult Cardiac 
Surgery of the EACTS/EACTA guidelines21 that there is a “lack of perioperative bleeding and 
transfusion rates as primary end points in these studies”, and that larger preferably multicenter 
“RCTs are required to determine the added value of individual heparin management”.  
5.2 PLATELET FUNCTION AFTER CPB AND PLATELET TRANSFUSION 
In Study III we analysed platelet function with ROTEM and ROTEM®platelet before and 
after CPB, and after platelet transfusions. We found significantly impaired results in all 
parameters after CPB. After platelet transfusion, ROTEM parameters, except INTEM CT, 
improved significantly, but of the ROTEM®platelet parameters only TRAPTEM increased 
significantly. Ten out of 23 patients received platelet transfusions based on clinical indications. 
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Significant risk factors for platelet transfusion included higher EuroSCORE II values and a 
longer duration of surgery and CPB time, in accordance with previous studies.87 EXTEM CT 
and TRAPTEM were significantly impaired in the transfused group before the platelet 
transfusions, compared with the group not receiving transfusion. 
The decreases in ROTEM results and platelet count after CPB correlate well with previous 
findings after CPB.11 However, the ROTEM®platelet results in our study all decreased 
significantly compared with pre-bypass values in contrast to findings where platelet function 
was tested with the Multiplate-instrument and only ADP and arachidonic acid-triggered 
aggregation was significantly decreased after CPB.15 
Our findings regarding a significant increase of TRAPTEM after platelet transfusion may be 
interpreted with previous findings in mind, where an in-vitro study showed that platelet 
function decreases over storage time measured by Multiplate.88 TRAP-induced aggregation 
in that study was better preserved (65%) at day 7 than both ADP (5%) and arachidonic acid 
(12%).  
ROTEM parameters were close to within normal range after CPB and before platelet 
transfusion, even if significantly decreased compared with baseline. Regarding the 
ROTEM®platelet results, ARATEM and ADPTEM were below normal range and together 
with TRAPTEM they all significantly decreased at this time point after CPB and before 
platelet transfusion as compared to baseline indicating an impaired platelet function. 
ROTEM is commonly used to monitor the perioperative coagulation status. The main 
advantage of the method is a rapid assessment of the concentration of clotting factors, 
platelet contribution to clotting, fibrinogen levels, heparin effect and fibrinolysis. The 
platelet contribution is based on the platelet count, while the platelet function is less well 
reflected with tissue factor as agonist in the ex-tem reagent. “The ROTEM® delta and sigma 
tests are not sensitive to the effects of the platelet inhibitors Aspirin®, clopidogrel and 
Reopro®”, and ROTEM®platelet is instead recommended according to the manufacturer 
(Guide to ROTEM® Analysis, www.rotem.de/en/products/rotem-platelet/ ). Moreover, they 
state that “the effect of von Willebrand factor is not detected. Furthermore, a normal 
ROTEM® does not exclude the anticoagulants Orgaran®, pentasaccharide, low-molecular-
weight heparin as well as oral anticoagulants such as Warfarin®. For analysis of these 
factors, other diagnostic tests have to be performed“. To assess the platelet function in 
patients with on-going anti-platelet therapy other POC devices are considered more specific, 
including platelet function analyser (PFA-100) (Siemens Health Care Diagnostics Inc, 
Deerfield IL), Multiplate (Roche, Basel, Switzerland), Plateletworks® (Helena laboratories, 
Beaumont, TX, USA) or Verify Now (Accumetrics, San Diego, CA, USA). These 
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instruments are all based on platelet activation with specific platelet aggregation agonists but 
use slightly different techniques. It has not to our knowledge been shown that any of the 
instruments is superior to any of the others in predicting bleeding risk.  ROTEM®platelet 
has been developed to measure platelet function, after agonist activation, similarly to the 
other POC instruments. We aimed to evaluate the potential use of ROTEM®platelet as a 
complement to ROTEM, which is routinely used in our centre.  
We are aware of one earlier study investigating ROTEM®platelet and Multiplate before and 
after cardiac surgery with CPB. In the study by Petricevic et al.64 when evaluating bleeding 
after CPB, platelet function was impaired 5–10 min after protamine administration in all 
ROTEM®platelet and Multiplate tests but ROTEM®platelet TRAPTEM. Results after 
protamine administration demonstrated the best correlation with 24-hour postoperative chest 
tube drainage. Both devices provided similar predictability for postoperative chest tube 
drainage and packed red blood cell transfusion requirements. The latter was associated with 
the degree of platelet inhibition and the number of pathways inhibited determined respective 
cut-off values. In contrast to our study, where surgery was delayed for at least five days after 
last intake of clopidogrel, approximately 10% of their patients were on clopidogrel and usually 
discontinued on admission, which in turn, resulted in different pre-operative clopidogrel-free 
intervals, although not presented. Additionally, they did not report if patients were on new oral 
anticoagulant drugs nor did they evaluate risk factors for platelet transfusion and impact of 
platelet transfusion on the tests. Moreover, the duration on CPB was considerably longer in 
our patients with a median duration of 117 (mean 128) and 193 (mean 202) minutes for non- 
and platelet transfused patients, respectively, compared with a mean of 103 and 121 minutes 
in their patients with normal 24-hour postoperative bleeding (mean 586 mL) and excessive 
bleeding (25th percentile, mean 1454 mL), respectively. Despite the large mean bleeding 
volume in their excessive bleeding group and significantly reduced ARATEM and ADPTEM 
tests none of the patients received platelet transfusions. Interestingly, mean TRAPTEM AUC 
was not significantly changed after CPB and protamine in their study, whereas all three 
ROTEM®platelet AUC values were significantly decreased in our study. These differences 
may be due to the longer duration of CPB in our study, although absolute ROTEM®platelet 
AUC values could not be compared, as we collected blood in citrated plastic tubes and they 
used heparin tubes. 
Administration of platelets tends to be based on empiric data instead of coagulation testing and 
algorithms. According to Goodnough89 47% of transfusions of platelets were deemed 
inappropriate when reviewing 30 patients in 18 different centres undergoing CABG. 
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Transfusions of platelets, even in smaller quantities, may add risks to these already vulnerable 
patients. “The American Association of Blood Banks (AABB) recommends against routine 
prophylactic platelet transfusion for patients who are non-thrombocytopenic and have cardiac 
surgery with CPB. The AABB suggests platelet transfusion for patients having CPB who 
exhibit perioperative bleeding with thrombocytopenia and/or with evidence of platelet 
dysfunction.”.33 Conversely, Perek et al. showed that routine transfusion of platelets to patients 
undergoing elective operations for ascending aortic aneurysm decreased risk of re-intervention 
due to bleeding90. 
Patients in our study receiving platelet transfusion had significantly longer duration of surgery 
and time on CPB.  Despite larger intraoperative bleeding, platelet count did not differ 
significantly between platelet transfused and non-transfused patients nor did the postoperative 
blood loss. The latter finding strongly indicates that platelet transfusion improved platelet 
function as exemplified with significantly increased TRAPTEM results. 
Patients will most likely benefit from any measures taken to reduce platelet activation and 
hemodilution. Such measures could include minimizing prime volume in the CPB circuit by 
reducing lengths of the tubings and optimising devises. This would decrease the hemodiluting 
effect on platelets, erythrocytes and coagulation factors. Centrifugal pumps are also considered 
to reduce trauma of blood cells and will also contribute to minimizing priming volume. In 
addition, Khan et al.91 found that individualised heparin dosage and protamine titration 
reduced platelet transfusion rate from 50% to 22% of the patients in a retrospective study. 
Those findings are supported by Shigeta et al. reporting heparin-protamine titration restoring 
platelet response to thrombin and attenuating platelet granule secretion during reversal of 
heparin.92 
 
5.3 APROTININ IN ISOLATED CORONARY SURGERY PATIENTS ON DAPT 
In the retrospective observational Study IV, we presented the administration of aprotinin in 
patients undergoing isolated first-time coronary surgery in our center between 2006-2014. 
After 2007, when aprotinin was suspended in Europe, aprotinin’s use was limited to patients 
on DAPT i.e. on clopidogrel and aspirin, and with platelet aggregation <85% on the day of 
procedure, in whom surgery could not be postponed until aggregation had normalized. A 
comparison of demographic and procedural variables, and clinical outcome parameters of 
patients who underwent coronary surgery and administered aprotinin during both time periods 
indicated that, in spite of a higher operative risk according to EuroSCORE I and a longer CPB 
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time, patients administered aprotinin between 2008 and 2014 had similar clinical outcomes 
and transfusion needs as patients given aprotinin during the prior 2 years. 
Platelet function testing has been recommended as an alternative to fixed discontinuation times 
to guide interruption of antiplatelet treatment before coronary surgery.93 The 2017 
EACTS/EACTA guidelines21 state that “Platelet function testing may be considered to guide 
the decision on the timing of cardiac surgery in patients who have recently received P2Y12 
inhibitors or who have ongoing DAPT”. In patients administered clopidogrel within 5 days of 
off-pump CABG surgery, Kwak et al.24 reported that the platelet inhibitory response to 
clopidogrel according to thromboelastography platelet mapping predicted augmented bleeding 
volume and transfusion need independent of the discontinuation time of antiplatelet therapy.24 
In patients on clopidogrel within 7 days before on-pump coronary surgery, Dalén et al. 
reported that PlateletWorks® ADP-induced platelet aggregation significantly correlated 
inversely with postoperative bleeding volume and predicted blood loss more consistently than 
timing of clopidogrel discontinuation.26 A strategy considering preoperative platelet function 
(ADP-induced platelet-fibrin clot strength determined by thrombelastography) to define 
timing of coronary surgery in patients on clopidogrel resulted in shorter waiting times (mean 
2.7 days) compared with recommended in 2017 EACTS/EACTA guidelines21 (³5 days), 
without a significant difference in 24-hour postoperative bleeding volume and transfusion 
needs compared with patients not administered clopidogrel.25 
In our center, platelet aggregation is tested in all patients with clopidogrel discontinuation ³5 
days before coronary surgery. Patients on clopidogrel with platelet aggregation <85% on day 
of surgery are regarded as having a high risk for disproportionate perioperative bloods loss and 
to have indication for aprotinin. Two RCTs have assessed the possible advantages of aprotinin 
in patients on DAPT before cardiac surgery. Akowuah et al. compared two different strategies 
in 50 patients in need for urgent coronary surgery: the intervention group remained on aspirin 
and clopidogrel treatment for 5 days prior to surgery and were given intraoperative aprotinin, 
while the control group was administered placebo capsules instead of aspirin and clopidogrel 
for 5 days and placebo infusions during surgery.59 The number of transfused PRBC units was 
significantly reduced in the aprotinin group. Additionally, 3 patients in the placebo group 
versus none in the treatment group had a myocardial infarction. In the other RCT by van der 
Linden et al., 75 patients with unstable angina administered clopidogrel <5 days before 
coronary surgery were randomized to either full-dose aprotinin or saline.60 In patients 
receiving aprotinin, postoperative bleeding volume, volume of transfused PRBC and platelets, 
and the rate of patients given blood products were significantly reduced. The possible benefits 
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of aprotinin still need to be assessed in patients on the newer P2Y12 inhibitors (ticagrelor or 
prasugrel) who require urgent coronary surgery. 
 
5.4 CLINICAL IMPLICATIONS 
Study I, a small pilot RCT, indicated that patients randomized to HeProCalc management 
obtained a significantly lower protamine dose compared with patients randomized to weight-
based dosing. ACT levels after CPB were similar in both groups. HeProCalc management 
for heparin reversal also suggested less postoperative blood loss, while not differing 
significantly between the groups. The latter finding needed to be investigated in a larger 
cohort.  
The results of the larger Study II indicate that the HeProCalc algorithm does not reduce 
postoperative blood loss or transfusion rate significantly when compared with heparin and 
protamine dosed by weight. Further larger multicenter RCTs evaluating primarily 
postoperative blood loss and transfusion rate are needed to more clearly define the value of 
individual heparin management. However, Study II showed that individual 
heparin/protamin management with the HeProCalc algorithm is feasible. 
Study III suggests that use of ROTEM®platelet, in addition to ROTEM, which is widely used 
to guide transfusions in bleeding patients, may be useful to predict platelet function and if 
platelet transfusions are needed. Activation with TRAPTEM seems to be sensitive both to 
decreased and increased platelet function, although this pilot study was based on rather few 
observations. Larger clinical studies are needed to establish appropriate indications for platelet 
transfusions in cardiac surgery. 
In Study IV, the clinical use of aprotinin fell significantly after the closure of the BART RCT 
in 2007. Nevertheless, highly selected patients taking clopidogrel <5 days before coronary 
surgery, with platelet inhibition >15 % on day of surgery and in whom surgery was not delayed 
continued to be administered aprotinin. Notwithstanding a higher operative risk according to 
EuroSCORE I and time on CPB, patients administered aprotinin between 2008 and 2014 did 
not have significantly different clinical outcomes and transfusion rates compared with those 
patients given aprotinin during the prior 2 years. This indicates that aprotinin administration 
still provides expected control of bleeding and transfusion rate in patient on clopidogrel and 
aspirin undergoing coronary surgery. Further studies are required to assess the use of aprotinin 
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in patients administered other platelet inhibitors, e.g. ticagrelor or prasugrel, and in need of 
urgent coronary surgery. 
 
5.5 LIMITATIONS 
In Study I-IV blood samples for ACT/HTC measurements were not performed by separate 
study personnel but were conducted according to standard clinical practice by clinically 
involved nurses and perfusionists. In the RCT Study I, no effort was made to cover group 
assignment, which potentially may have influenced results. Another limitation of Study I-
II was that ATIII levels were not included in the study protocol and hence not systematically 
analyzed before surgery. However, this would have made it more difficult to include patients 
due to additional costs as it is not part of our clinical routine and sampling had to be 
undertaken the day before surgery. Additionally, it would have required an algorithm to 
handle patients with specifically low ATIII levels as well as stratification of patient within 
the randomization. In the 2011 STS/SCA Blood Conservation Clinical practice Guidelines70 
state that ATIII “concentrates are indicated to reduce plasma transfusion in patients with 
AT(III) mediated heparin resistance immediately before cardiopulmonary bypass.”(Class I, 
Level A, Figure 16). However, heparin resistance was defined as the failure to achieve ACT 
of at least 400-480 seconds after a heparin dose of 400-1,200 IU/kg and not according to a 
specific ATIII level.70 Interestingly, the 2018 published guidelines of STS/SCA/AmSECT 
for anticoagulation during CPB,44 do not give any specific recommendation for 
administration of ATIII, although it states that “the pharmacodynamics of unfractionated 
heparin are highly dependent on the level and function of plasma ATIII”. On the contrary, 
the 2017 EACTS/EACTA guidelines recommend that “AT supplementation is indicated in 
patients with AT deficiency to improve heparin sensitivity”, without stating any specific 
threshold value (Class I, Level B).21( Figure 16) 
In Study I postoperative blood loss was calculated from end of surgery until the next 
morning, whereas variable was measured more specifically in Study II, by measuring blood 
loss during the first 12 hours after end of surgery. Additionally, one may argue that the 9 
patients in Study II who underwent reoperation due to surgical bleeding should not have 
been excluded. Nevertheless, irrespective of whether these 9 patients were excluded or not, 
no statistical differences between the 2 groups were found regarding bleeding and 
transfusion rate. 
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Study III had several limitations. Besides the observational design of the study and the small 
sample size, there are some aspects to keep in mind when interpreting the results. A larger 
sample size might have shown significantly improved results regarding both ARATEM and 
ADPTEM, thus implying a risk of type II-error.  
Another aspect is the fact that conducting platelet function test with a low platelet count may 
influence the results. Median platelet count in the whole cohort of our study was 101 x 109/L 
after CPB and before platelet transfusion. ARATEM and ADPTEM were below normal 
range after CPB and before platelet transfusion. A platelet count below normal may influence 
the results, but only moderately at a platelet count around 100x109/L 94, 95. The median 
platelet count in our patients who received platelets was 87.5 (77.2/121) x109/L after CPB 
and before platelet transfusion (T1), and after platelet transfusion the platelet count increased 
to 139 x 109/L (124/173, p=0.002). Thus, if the platelet concentration would have had a 
significant influence on the ROTEM®platelet tests after platelet transfusion, one would have 
expected all three tests to improve significantly. However, as only TRAPTEM AUC 
improved significantly after platelet transfusion one may argue that the platelet count is 
unlikely to have had a significant influence.  
Study I-IV were performed in a single institution and one group in Study IV included a 
small number of patients (42=6 per year on average) during the 7-year study period during 
which aprotinin administration was limited to very selected patients. Also, the two groups 
of Study IV differed in demographic and procedural characteristics, including a longer CPB 
mean time and higher operative risk according to EuroSCORE I in patients undergoing 
cardiac surgery between 2008 and 2014. Finally, the results of the retrospective Study IV 
should be interpreted with caution due to its observational design. 
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6 CONCLUSIONS 
The specific conclusions were: 
• In a randomized controlled pilot study patients, who were administered heparin and 
protamin according to the HeProCalc algorithm, received a significantly lower dose of  
protamine compared with a control group, where the protamine dose was dosaged 
according to body weight.  
 
• The HeProCalc algorithm did not significantly affect postoperative blood loss or 
transfusion requirement compared with dosage of heparin and protamine based on 
body weight. 
 
• ROTEM®platelet with thrombin activation, TRAPTEM, improved significantly, 
indicating that platelet transfusion may reverse cardiopulmonary bypass induced 
platelet dysfunction. 
 
• Despite a significantly higher operative risk and a longer CPB time, patients receiving 
aprotinin between 2008 and 2014 did not have significantly different clinical outcomes 
or transfusion rates compared to those receiving aprotinin during the prior two years. 
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